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Abbreviations 
 
ANOVA - analysis of variance 
AP - alkaline phosphatase 
APP - amyeloid precursor protein 
Arg - Arginase 
BBB - blood brain barrier  
BDNF - brain derived neurotrophic 
factor  
BME - Basal Medium Eagle 
BSA - bovine serum albumine  
CCL -  chemokine C-C motif ligand 
CCR - chemokine (C-C motif) receptor 
CD - cluster of differentiation  
CFA - complete Freund’s adjuvant  
CNS - central nervous system  
CNTF - ciliary neurotrophic factor 
CS - clinical score  
CSF – colony stimulating factor 
CT - computer tomography 
CX3CR1 - Chemokine CXC motive 
receptor  
CX3CL1 - Chemokine CXC motive 
ligand 
DABCO - 1,4-diazabicyclo[2.2.2]octane 
DAPI - 4',6-diamidino-2-phenylindole 
DAP12 - DNAX activation protein of  
12 kDa 
DTT - dithiothreitol 
DMEM - Dulbecco’s Modified Eagle's 
Medium 
 
 
DMSO - dimethylsulfoxide  
DNA - deoxyribonucleic acid 
dNTP – deoxynucleotide triphosphate  
EAE - experimental autoimmune 
encephalomyelitis 
EB - embryoid body  
EDTA - ethylenediaminetetraacetic acid 
EGF - epidermal growth factor 
EGFR – epidermal growth factor 
receptor 
ESC - embryonic stem cell  
ESdM - embryonic stem cell derived 
mircoglial precursor 
ERKs - extracellular-signal-regulated 
kinases 
FACS - fluorescence activated cell 
sorting 
FCS - fetal calf serum  
FGF - fibroblast growth factor  
Fig - figure 
Fizz - found in inflammatory zone 
Fn - fibronectin  
G-CSF - granulocyte-colony stimulating 
factor 
GAP43 - growth associated protein 43 
GAPDH - glyceraldehyde-3-phosphate 
dehydrogenase 
GFAP - glial fibrillar acidic protein  
GFP - green fluorescence protein 
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GM-CSF - granulocyte macrophage 
colony stimulating factor  
hCG - human chorionic gonadotropin 
HE – hematoxylin/eosin 
HEK – human embryonic kidney 
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HSV – herpes simplex virus 
Iba1 - ionized calcium binding adaptor  
molecule 1 
ICM - inner cell mass  
IFN - Interferon 
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IGF- insulin-like growth factor 
IL - Interleukin 
iNOS - inducible nitric oxide synthetase  
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protein 
iPS - cell induced pluripotent stem cell  
ITAM - immunoreceptor tyrosine-based 
activation motif 
ITIM - immunoreceptor tyrosine-based 
inhibition motif  
ITS - Insulin-Transferrin-Selenite  
IU – international unit 
LB - lysogeny broth 
LIF - leukemia inhibitory factor  
LFB – luxol fast blue 
LOH – loss of heterozygosity 
LPS - lipopolysaccharide  
MAC – macrophage antigen 
MBP -myelin basic protein  
MCP-1 - monocyte chemoattactic 
protein 1  
MEF - murine embryonic fibroblast  
mg – milligram 
ml - millilitre 
MHC - major histocompatibility 
complex  
MIG - monokine induced by gamma 
interferon 
MMP – matrix metallo proteases 
MOG - myelin oligodendrocyte 
glycoprotein  
MRT - magnetic resonance tomography 
MS - multiple sclerosis  
NGF – nerve growth factor 
nGS - normal goat serum 
NK – natural killer 
NT-3 - neurotrophin-3  
NO - nitric oxide 
OA – okadaic acid 
PBS - phosphate buffered saline  
PCR - polymerase chain reaction  
PE - phycoerytin 
PDGF - platelet-derived growth factor 
Pen/Strep – penicillin/ streptomycin 
PET - positron emission tomography 
PFA - paraformaldehyde  
PMSG - pregnant mare serum 
gonadotrophin 
PLL - Poly-L-lysine  
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PGK - phosphoglycerate kinase 
PTEN - phosphatase and tensin homolog 
qRT – quantitative real time 
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ROI – reactive oxygen species 
RT – real time 
SEM - standard error of the mean 
SiglecH - sialic acid binding 
immunoglobulin -like lectin H 
SIRP - signal-regulatory-protein  
SPECT - Single photon emission 
computed tomography 
SR – scavenger receptor  
SSEA - stage-specific embryonic antigen 
SVZ – subventricular zone 
TAM – tumor associated macrophages 
TGF-β - transforming growth factor β  
TLR - toll-like receptors  
TNFα - tumor necrosis factor alpha  
TREM2 - triggering receptor expressed 
on myeloid cells 2 
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1. Introduction 
 
1.1. Microglia 
 
1.1.1. General Introduction 
Two main cell types can be found in the central nervous system (CNS): neurons and glial 
cells. Neurons are exitable cells which can form neuronal networks and transmit 
information throughout the CNS.  Glial cells support and protect neurons, therefore they 
are known as supporting cells of the nervous tissue. They are roughly divided into two 
subgroups, macroglia and microglia. Astrocytes and oligodendrocytes belong to the class 
of macroglia. 
Microglia were first described in detail by del Rio Hortega in 1919 (del Rio Hortega, 
1919) (Fig. 1.1). They are the resident immune cells which are the first line and main 
component in the active immune defense of the CNS. They are found throughoutly in the 
adult brain and compromise about 10 % of all brain cells (Ransohoff and Perry, 2009).  
 
 
Fig. 1.1: Left: Drawing of ramified microglia by del Rio Hortega (del Rio Hortega, 1919 ). Right: 
Photomicrograph of silver stained microglia (del Rio Hortega, 1932). 
 
Microglia respond to injury as well as to brain disease, they are known to scavenge 
invading microorganisms and dead cells and furthermore act as immune effector cells. 
Thus, they are key players in innate immunity and brain homeostasis in the immune 
privileged brain (Rivest et al. 2009).  Additionally, microglia most likely contribute to the 
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onset of or increase of neuronal degeneration as well as inflammation in many brain 
diseases by producing detrimental factors like superoxide anions, nitric oxide (NO) or 
pro-inflammatory cytokines. However, microglia cells are also able to produce 
neurotrophic and neuroprotective molecules such as nerve growth factor (NGF), 
indicating a role in neuronal survival in cases of brain injury. Therefore, they are 
considered to be of double-edged nature, as they have both beneficial and detrimental 
effects.  
 
1.1.2. Origin of microglia 
During development in mice, microglia populate the brain in two waves. First, ionized 
calcium binding adaptor molecule 1 (Iba-1) positive cells appear in the neuroepithelium 
during embryonic development (E9.5-10.5) before blood circulation is established (Alliot 
et al., 1999). It was shown by Ginhoux et al that these cells are derived from primitive 
macrophages in the yolk sac (Ginhoux et al., 2010). The second wave takes place from 
E13.5 until birth, when an increase in Iba-1 positive cells in the brain and spinal cord 
takes place (Chan et al., 2007). Microglial precursor cells which matured in the CNS 
during fetal development retain an immature phenotype resembling the M2 subtype of 
macrophages (see chapter 1.1.5) (Rae et al., 2007). 
Microglia were believed to be of mesodermal origin, as originally suggested by del Rio 
Hortega in 1919. Until today, this hypothesis still lacks concrete evidence and is a matter 
of debate (Chan et al., 2007). Therefore, it was thought to be possible that microglia can 
arise from the neuroectodermal lineage like macroglia and neurons as well (Fedoroff et 
al., 1997). It has been suggested that they also might emerge from circulating blood 
mononuclear cells (Perry et al 1985; Biber et al 2007), though microglia are present in 
the developing CNS before vascularization (Alliot et al., 1999). 
A subset of microglia is derived from bone marrow monocytes, though it has been shown 
that the transition is a rare event and takes place only under irradiation, lesion or 
inflammation (Shechter et al., 2009, Mildner et al., 2007, Kigerl et al., 2009).  
In addition, Ajami et al have recently shown that blood-derived monocytes infiltrating 
the brain during experimental autoimmune encephalomyelitis (EAE) do not contribute to 
the resident microglia in the CNS (Ajami et al., 2011, Mildner et al., 2007). 
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During the last years, evidence arouse that resident microglia emerge through primitive 
yolk sac macrophages derived from haematopoietic stem cells via a myeloid progenitor 
state (Fig.1.2) (Ransohoff and Cardona 2010; Ginhoux et al., 2010, Alliot et al., 1999).  
 
 
Fig.1.2: Relation of microglia to CNS cells. Microglia are the only cells of haematopoietic origin in the 
parenchyma of the CNS and migrate there during development (Ransohoff and Cardona, 2010).  
 
These findings go along with older publications which have already shown that yolk sac 
macrophages are able to proliferate after migrating into the embryonic tissue (Cossmann 
et al., 1997). Thus, microglia are most likely derived from primitive yolk sac 
macrophages which differentiate into microglial cells. 
 
1.1.3. Characterization of microglia 
Microglia characterization regarding surface expression markers is not a simple task, as 
they share most markers with macrophages. Nevertheless, microglia have a number of 
specific properties which distinguish them from other macrophages in the body. Inside 
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the brain, the density of microglia cells seems to be determined by specific different 
features of brain regions. For example, density of microglia in mice varies from 5 % in 
the cerebral cortex to 13 % in the substantia nigra (Lawson et al., 1990). This diversity of 
microglia continues with their morphology, which ranges from a highly ramified 
appearance with multiple cell processes to round phagocytic cells. Concerning the 
proliferation, microglia behave like bone marrow myeloid progenitor cells (Alliot et al., 
1991) and share the expression of the stem cell marker cluster of differentiation (CD) 34. 
Opposed to splenic macrophages or alveolar lung macrophages, adult quiescent microglia 
express low levels of cell surface marker CD45, major histocompatibility complex 
(MHC) class II and Fc receptor molecules. However, several studies defined the 
following surface marker profile for microglia: CD68+, CD45 low, CD11b+, CD11c 
high, MHC class II+, Iba1+ and F4/80+ (Guillemin and Brew, 2004; Napoli et al., 2009). 
In addition, microglia express co-stimulatory molecules CD86 and CD40, though in low 
levels (Aloisi et al., 2000). Furthermore, microglia share some phenotypic and functional 
features of neural stem cells, including the expression of nestin (Yokoyama et al., 2004). 
This feature cannot be found in any other population of tissue-resident macrophages. 
 
1.1.4. Microglia states 
In the adult brain microglia can switch inbetween two states (Fig. 1.3).  
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.3: Resting and activated microglia state (Perry et al., 2007) 
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The first state is the so called “resting” state, in which highly ramified microglia carry out 
active tissue scanning in the brain. The processes of microglia are continuously moving, 
scanning the whole space of the CNS parenchyma every few hours (Nimmerjahn et al., 
2005). Resting microglia release immunosuppressants as well as neurotrophic factors and 
establish short time contacts with neurons to check on their health status (Hanisch 2002). 
They furthermore secrete cytokines and chemokines which are crucial for neuronal 
survival (Linnartz et al., 2010). This resting state is regulated via immunosuppressive 
mediators such as Interleukin (IL) 10 or transforming growth factor β (TGF-β) present in 
the interstial fluid (Ransohoff and Perry, 2009). Furthermore, interaction of microglia 
with astrocytes and neurons through neurotransmitter receptors plays an important role in 
microglia state transduction (Graeber et al., 2010, Hanisch and Kettenmann 2007). 
Especially chemokine CXC motif (CXC) 3 ligand 1 (CX3CL1) secreted by neurons is 
involved in maintaining the resting state of microglia and is sensed via the CX3C 
receptor 1 (CX3CR1) expressed by microglia. 
The second state is the “activated” state which occurs in response to pathology and a 
disturbed CNS homeostasis, leading to phagocytosis, migration and release of 
inflammatory cytokines. A variety of stimuli leading to activation of microglia is known, 
including viral envelopes, bacterial cell wall components, pathological proteins or serum 
factors crossing the blood brain barrier (BBB) (Adams et al., 2007, Heppner et al., 2011). 
Microglia are able to recognize these stimuli through toll like receptor (TLR) 1 to 9 or 
complement receptor macrophage antigen 1 (MAC-1) (Lehnardt et al., 2010). Upon 
signals of damaged or non-functional cells, microglia migrate to the affected site and then 
act as scavenger cells. This migration is mostly mediated by “find-me” signals emitted by 
dying cells (Blume et al., 2011). Dead cells are recognized through a variety of molecules 
such as triggering receptor expressed on myeloid cells 2 (Trem2), CD36 or Scavenger 
Receptor 1B (SR1) (Napoli and Neumann 2009). The process of microglial phagocytosis 
is mainly regulated by environmental signals. Furthermore, activated microglia are also 
known to promote neuroprotection via secretion of neurotrophic factors like NGF 
(Elkabes et al., 1996). The major functions of activated microglia resemble those of 
tissue macrophages and include phagocytosis, antigen presentation and the production of 
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chemokines, oxidative radicals or NO (Benveniste et al., 2001). 
In the resting state microglia mostly produce neurotrophins, whereas cytokines are 
produced upon stimuli (Elkabes et al., 1996). For example, cytokine gene transcription is 
induced by lipopolysaccharides (LPS) or interferon (IFN) γ. An initial release of some 
cytokines such as tumor necrosis factor (TNF) α has an autocrine impact on further 
cytokine release. Cytokines play a crucial role in regulation of surface marker expression 
as a requirement for chemotaxis and cellular interactions like antigen presentation or 
apoptosis (Hanisch et al., 2002). 
 In summary, the activated state of microglia is very dynamic and diverse, leading to 
different functional properties, ranging from neuroprotective to neurotoxic consequences 
(Biber et al., 2007; Nimmerjahn et al., 2005; Hanisch et al., 2007).  
 
1.1.5. Subdifferentiation of microglia 
According to recent studies, immune responses have to be well controlled to have a 
beneficial effect on neurons. Otherwise, impaired regulation of immune responses can 
lead to neuronal loss and even result in autoimmune diseases (Butovsky et al., 2005). 
Thus, pathways involved in pro- and anti-inflammatory processes have to be tightly and 
precisely regulated. 
The double-edged nature of migrolia activation, which can lead to toxic or protective 
effects in the brain, depends on the secretion of anti- or pro-inflammatory molecules. 
Beside their activation states, microglia are further divided into a range of different 
subtypes, of  which the M1 and M2 subtype represent the extremes and are distinctive in 
regards to surface receptors, cytokine production and effector functions (Fig. 1.4) 
(Mantovani et al., 2004).  
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Fig. 1.4: Overview of M1 and M2 microglia subtype properties. Cells develop different functional 
properties in response to their environment. M1 polarization through IFN-γ and TNF-α leads to expression 
of iNOS, TNF-α, reactive oxygen intermediates (ROI) and IL-6, which lead to cytotoxic function. M2 
polarization through IL-4 and IL-13 leads to increased levels of Arginase (Arg) and Scavenger Receptors 
(SR) and cells are more prone to immunoregulatory functions (Mantovani et al., 2004). 
 
The first one is the type I microglia (M1), which resembles the classically activated pro-
inflammatory microglia. This microglia type responds to microbial compounds, pro-
inflammatory cytokines and lymphokines secreted by type 1 T helper (Th) cells 
(Mantovani et al., 2004; Michelucci et al., 2009). Upon stimulation, microglia present 
higher levels of MHC class I and II, CD80 and CD86 and show enhanced antigen 
presentation capability (Benveniste et al., 1996). They furthermore respond through a 
higher motility and increased proliferation rates termed microgliosis (Nimmerjahn et al., 
2005, Ransohoff 2007). In addition, they secrete pro-inflammatory cytokines such as IL-1 
and TNF-α (Hanisch and Kettenmann, 2007), free radicals like NO and superoxide 
anions (Goerdt and Orfanos, 1999). Although these molecules are crucial for the defense 
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of the brain towards pathogens, their expression leads also to a cytotoxic effect and 
collateral damage to healthy tissue (Ding et al., 1988). M1 stimulation also triggers 
CXCL10 secretion, which is involved in microglia recruitment via its receptor CXCR3 
(Rappert et al., 2004). 
 
The second type is the type II microglia (M2), which resembles the alternatively activated 
anti-inflammatory subtype (Michelucci et al., 2009; Kigerl et al., 2009). Molecules 
involved in activation of this subtype are molecules derived from type 2 Th cells like IL-
4, IL-10, IL-13 or TGF-β (Goerdt and Orfanos, 1999). In the healthy brain, the 
alternative activation of microglia is mostly found in presence of apoptotic cells, which 
require phagocytic activity without inflammatory responses. Type II microglia are known 
for their anti-inflammatory properties, as they express receptors involved in endocytosis 
and phagocytosis like SR1 (Stein et al., 1992). Furthermore, M2 polarized microglia have 
been shown to secrete neuroprotective factors such as insulin-like growth factors (IGF) or 
NGF (Butovsky et al., 2006). M2 microglia secrete a variety of immune-suppressive 
cytokines such as TGF-β and IL-10 (Napoli and Neumann, 2009). They play an 
important role in mediating tolerance and abating inflammatory processes. 
 
This broad spectrum of microglia effects allows a delicate balance of pro- and anti-
inflammatory immune responses in the brain. Furthermore, in vitro studies showed that 
the subtypes have different effects on neurogenesis and oligodendrogenesis. Type I 
microglia activated by IFN-γ decreased neurogenesis and oligodendrogenesis, whereas  
type II microglia activated by IL-4 had the opposite effect (Butovsky et al., 2006). 
 
1.1.6. Embryonic stem cell derived microglia 
During the last years, primary microglia have been commonly used to study microglia 
function. Several methods for isolation of primary microglia have been established and 
range from fluorescence activated cell sorting (FACS) to isolation from mixed glial 
cultures (Ford et al., 1995, Giulian and Baker 1986). All of those methods have the 
drawback to be time-consuming and to yield only a low number of cells. Thus, they are 
not suitable for biochemical assays requirering high cell numbers.  
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Thus, oncogenically transformed microglial cell lines such as BV2 and N9 have been 
used, which have been immortalized via retroviral transfection with v-raf and v-myc. 
(Bocchini et al., 1992). The immortalization process and their lack of some microglia 
properties (Blasi et al., 1990, Horvath et al., 2008) make these cell lines only a poor 
substitute to study microglia function. 
 
Recently, a differentiation protocol for microglia-like cells from murine embryonic stem 
cells (ESCs) was described (Tsuchiya et al., 2005). By modification of this protocol, a 
protocol for ESC differentiation into microglia was established (Napoli et al., 2009; 
Beutner et al., 2010).  The protocol results in stable and pure proliferating cultures of 
ESC-derived microglial precursor (ESdM). ESdM derived from C57BL/6 ESCs express 
microglia markers like CD11b, CD11c, CD29, CD45, CD68 and Iba-1, but are negative 
for stem cell markers like CD117.  ESdM are also positive for CD86, indicating that they 
are capable of antigen presentation. ESdM express CX3CR1 and are migratory active 
towards the chemokine CX3CL1. Furthermore, ESdM are capable of phagocytosing Aβ 
and fluorescent microsphere beads. Additionally, ESdM engraft as microglial cells into 
brain tissue upon transplantation (Napoli et al., 2009). Analysis of the cytokine gene 
transcription showed a similar inducibility of cytokines of primary microglia and ESdM. 
Therefore, ESdM can be considered an adequate substitute for primary microglia and can 
be used in studies aiming at microglia function in neurodegenerative diseases.
 
 
 
1.2. Multiple Sclerosis 
 
1.2.1. General Introduction 
Multiple Sclerosis (MS) is a chronic inflammatory neurodegenerative disease which leads 
to demyelination of neurons in the CNS (Compston and Coles, 2002). With an estimated 
prevalence ranging between 2 and 150 per 100000, MS is one of the most common 
neurologic diseases, especially among younger people (Rosati et al., 2001). Until now, 
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the cause of the disease is not known, although several environmental risk factors like 
lack of sun exposure have been found (Ascherio et al., 2007). 
MS can be classified into four subtypes according to the United States National Multiple 
Sclerosis Society: the relapsing-remitting, the secondary progressive, the primary 
progressive, and the progressive-relapsing form. The course of the relapsing-remitting 
subtype shows relapses with longer time periods of remission inbetween and is the most 
common form. Secondary progressive MS can be described as a follow-up of the 
relapsing-remitting form, in which patients begin to show neurologic decline between 
acute phases without remission phases (Compston and Cole, 2008). The primary 
progressive form of MS describes a disease course without remission phases after the 
time point at which the first symptoms appear (Miller et al., 2007). The last common 
subtype is the progressive relapsing form, which combines a steady neurologic decline 
with superimposed attacks (Lublin et al., 1996).  
The loss of effective signal conduction via the axons can lead to a broad variety of 
neurological symptoms, including muscle weakness, loss of coordination, visual 
problems or changes in sensation. Early symptoms include fatigue, double visions and 
visual disturbance, genereal muscle weakness and tremors. As disease progresses, the 
symptoms become more severe and can result in blindness, muscle spasm and paralysis 
(Compston and Cole, 2008). 
 
1.2.2. Pathology and role of microglia in multiple sclerosis 
In MS, the immune system carries out a destructive immune response against antigens of 
the CNS like myelin basic protein (MBP), proteolipid protein (PLP) and myelin 
oligodendrocytic protein (MOG). Subsequently, this reaction leads to demyelination and 
axonal injury within the white matter of the CNS (Fig 1.5).  
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Fig. 1.5: Pathogenesis of MS. Activated T cells and macrophages migrate from the blood stream to the 
CNS and initiate the inflammatory lesions through cytotoxic factors (CF). Activated microglia contribute to 
demyelination via secretion of CF, ROS and IL-1β (Mattson and Taub, 2004). 
 
Due to the demyelination, impairment of signal transmission occurs, axons are damaged 
and neurons are lost (Arnold and Matthews, 2002). Remyelination can occur in early 
phases of the disease, but the myelin sheath is not rebuilt completely. During the course 
of MS, scar-like plaques appear around the damaged axons, which are called lesions 
(Chari et al., 2007). 
Apart from the demyelination process, inflammation is another pathological hallmark of 
MS. The inflammation is mainly mediated by activated autoreactive T cells which invade 
the brain via the BBB and initiate an inflammatory response against autogens (Compston 
and Cole, 2002) and attack the myelin sheath (Wucherpfennig and Strominger, 1995). 
This attack in turn stimulates other immune cells like microglia and macrophages and 
leads to the secretion of inflammatory cytokines (Cannella and Raine, 1995). Despite of 
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the numerous beneficial functions of microglia, the activation of microglia has been 
implicated in the pathogenesis of a variety of CNS diseases. In case of MS, activated 
microglia cells produce MHC class II and present brain specific antigens to T cells 
(Dangond et al., 1997). They furthermore produce pro-inflammatroy cytokines, free 
radicals and matrix metalloproteases (MMP) (Benveniste et al., 1997). Inflammatory 
cytokines attract immune cells like lymphocytes and trigger the production of adhesion 
molecules, which in turn facilitate the immigration of cells through the BBB into the 
CNS. In summary, these processes lead to further recruitment of T cells, B cells and 
macrophages to the inflammation site. Autoreactive B cells start to produce antibodies 
against myelin antigens (Steinman et al., 2002). The inflammation process is further 
increased through histamine release by mast cells (Theoharides et al., 2007). It has been 
demonstrated that brain regions with a high grade of demyelination also contain high 
numbers of microglia (Bauer et al., 1994). The crucial role of microglia in MS is further 
underpinned by the finding that depletion of microglia attenuates EAE in presence of T 
cells (Huitinga et al., 1990). 
 
1.2.3. Treatment of multiple sclerosis 
Until now, there is no known cure for MS, though treatments aim at prevention of attacks 
and disability. Currently, most treatments involve immunosuppressants. Five medications 
have been proven as helpful: IFN-1a, IFN-1b, glatiramer acetate, mitoxantrone and 
natalizumab. All of those decrease the number of attacks in the relapsing-remitting form 
of MS. However, long term studies of side-effects are still not present (Comi et al., 
2009). Glatiramer acetate has been demonstrated to decrease microglial activation and 
thus have a beneficial impact on disease course (Ratchford et al., 2011). 
In attack phases, administration of corticosteroids leads to a decrease of acute symptoms. 
But this treatment does not have an impact on long term disease course or recovery 
(Burton et al., 2009). 
Current research is focused on better understanding of the course and the pathogenesis of 
MS. Furthermore, there is still need for therapies for the progressive subtypes of MS. 
Another major challenge is the improvement of treatments in general, especially 
concerning neuroprotection and regeneration. 
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The field of stem cell research has led to new approaches in addressing 
neuroinflammatory disorders including MS. Several cell types have been used for 
therapeutic approaches. To give an example, neural stem cells have been reported to 
migrate to inflammation sites in the CNS and to contribute to functional recovery and 
tissue repair (Pluchino et al., 2003). A similar beneficial effect was shown using bone 
marrow cells (Zappia et al., 2005).  
 
1.2.4. Experimental autoimmune encephalomyelitis 
For therapeutic studies concerning MS, the most commonly used animal model is the 
EAE. Like MS, it is an inflammatory demyelinating autoimmune disease which is 
mediated by T cells. EAE is inducible in common laboratory animals such as mice, rats, 
rabbits or primates. In mice, myelin proteins or peptides like MBP or MOG emulsified in 
adjuvant are used for induction of disease. Injection of this mixture leads to an 
inflammatory response to the protein (Billiau and Matthys, 2001). Co-injection with 
pertussis toxin decreases the BBB and allows immune cells to infiltrate the CNS tissue 
(Kerfoot et al., 2004). Depending on the antigen injected, different EAE forms can be 
induced. With MOG-peptides (aminoacids 30 to 55) the course of EAE will be the 
relapsing-remitting subtype. Around two weeks after immunization the first clinical 
symptoms appear, starting with decreased tail tonus and paralysis of the tail. Progression 
of symptoms is ascending up the body, first affecting the hind limbs and then the 
forelimbs (Fig. 1.6).  
 
 
 
 
 
 
 
 
Fig. 1.6: The left mouse displays clinical symptoms of EAE (clinical score of 3 with hind limb 
paraparesis), whereas the mouse to the right is healthy (Janeway´s Immunology 7th Edition). 
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Therefore, the symptoms reflect the anatomic location of the inflammatory lesions. In the 
relapsing-remitting form of EAE, recovery of symptoms can be complete or partial 
(Elhofy et al., 2002). 
Concerning the pathology, EAE mimics important aspects of human MS like progressing 
demyelination, inflamed lesions and axonal injury (Kornek et al., 2000). 
However, EAE cannot be considered to be completely equivalent to human MS, as it 
differs in time course and nerve inflammation. 
 
1.2.5. Neurotrophin 3 
Neurotrophin 3 (NT3) is a member of the neurotrophin family, which is involved in the 
homeostasis and regulation of the central and peripheral nervous system. Other members 
of this family are brain derived neurotrophic factor (BDNF) or NGF. 
NT3 is closely linked to the survival and maintenance of function of a variety of neural 
populations (Chen et al., 1997). NT3 interacts with the tyrosine related kinase C (TrK C) 
with high affinity (Lamballe et al., 1994) and with a lower affinity with TrK B and the 
low affinity NGF receptor. 
Receptors for neurotrophins are expressed on several different cell types, including 
lymphoid cells, cardiac cells, muscular cells or endothelial cells (Labouyrie et al., 1997; 
Donovan et al., 1996; Oichi et al., 1997; Ricci et al., 2000). Furthermore, expression of 
neurotrophin receptors was found in B cells (Kerschensteiner et al., 1999). 
The diversity of target cells mirrors the broad range of diverse biological effects. They 
play a crucial role in axonal outgrowth and neurogenesis as well as in neural survival 
(Kannan et al., 1992; Memberg et al., 1995).  Recent studies indicate that NT3 plays a 
role in mediating the bidirectional cross-talk between the immune system and the nervous 
system (Biber et al., 2007). Additionally, neurotrophins were shown to be endogenously 
expressed in lesion formation in MS (Hohlfeld et al., 2006). The linkage of neurotrophins 
and severity of MS in the post-relapse phase with complete remission which was shown 
by Caggiula in 2005 qualifies neurotrophins as promising candidates for studies of 
therapeutic approaches of MS (Caggiula et al., 2005). 
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1.3. Glioma 
 
1.3.1. General Introduction 
A glioma is defined as a CNS tumor type which arises from glia cells. They are primary 
tumors, occurring rather seldomly with an estimated prevalence of 15 cases for 100,000 
people (American Cancer Society, 2006). 
The world health organization (WHO) established a commonly accepted classification for 
brain tumors. In the recent version from 2007, gliomas represent the major group of brain 
tumors with 40%. Gliomas can be divided into several groups according to their cell type 
pendandts glia, astrocytes and oligodendrocytes and their WHO-grade (see table 1.1). 
 
Tab.1.1: Official classification of glioma according to the world health organization (WHO, 2007) 
WHO nomenclature WHO 
grade 
Histopathology 
Pilocytic astrocytoma 
 
I Low cell density, bipolar pilocytic cells 
Rosenthal fibres 
Low-malign 
astrocytoma 
II Low to minor cell density, fibric or gemistocytic 
astrocytes, some mitosis, few nuclear atypias 
Low-malign 
oligodendroglioma and 
oligoastrocytoma 
II Honeycomb-structure, low cell atypia, few mitosis 
Anaplastic astrocytoma III High cell density, cell and nucleus polymorphisms 
Anaplastic 
oligodendroglioma and 
oligoastrocytoma 
III Additional honeycomb-structures, mixed forms 
Glioblastoma IV High cell density, high number of atypias, necrosis, 
vascular proliferation 
 
Low grade gliomas (grade I and II) are considered as benign and not anaplastic; therefore 
a good prognosis for the patients can be stated. The average age of the first diagnosis of a 
low grade glioma is between 30 and 40 years (Ichimura et al., 2004). The medial survival 
time ranges between 7 to 8 years, depending on the time-point when the tumor changes to 
a malign tumor through increasing dysplasia. The low graded types of gliomas are 
growing slowly but infiltrative and can therefore reach an impressive size before first 
symptoms appear. 
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Gliomas with a WHO grade with II or higher are anaplastic and malignant. In case of 
glioblastomas, the median of survival after diagnosis ranges from 2 to 8 months, 
depending on the age of the patient (Scott et al., 1987; Curran et al., 1993). In this group, 
glioblastomas are the most prominent tumors and count for 23% of all brain tumors. 
Median age for first diagnosis is 64 years, the medial survival time with maximal therapy 
is 14.6 months (Stupp et al., 2005). Glioblastoma can arise de novo as primary or from 
existing lower-grade tumors as secondary glioblastomas (Kleihues et al., 1999), which 
differ a lot in molecular structures (Tso et al., 2006). Glioblastomas are characterized by 
rapid and infiltrative growth pattern and are diffcult to target in therapy. 
1.3.2. Symptoms of glioma 
As virtually every part of the central nervous system can be affected by gliomas, the 
range of symptoms which they cause is very broad. With an incidence of 50 %, head 
aches are the most prevalent first symptom (Forsyth et al., 1993). Depending on the 
histology, the location and growth rate of the tumor, gliomas can cause neurological 
misfunctions. Approximately 30 % of brain tumor patients show epileptical seizures 
(Glantz et al., 2003). Most patients suffer additionally from general symptoms like 
nausea, vomiting, sleepiness, dementia or changes in character properties (Glantz et al., 
2000). 
In histopathology, the different glioma types show a variety of cellular structures. Lower 
grade tumors show a wide morphological spectrum with low cell density, typical bipolar 
pilocytical cells and Rosenthal fibres. Malignant tumors display a high cell density with 
cell and nuclei atypias, development of vasculature and necrosis. 
In regard to pathophysiology, gliomas lead to changes in several brain structures and 
properties. One major hallmark for the depiction of tumors is the BBB breakdown, which 
is mediated by tumor capillaries (Dickman et al., 1989). 
Tumors with a size of 2 to 3 cm in diameter result in an increase in intracranial pressure, 
as the brain parenchyma cannot be compressed (Black et al., 1986). 
A variety of imaging diagnosis is available, ranging from computer tomography (CT), 
magnetic resonance tomography (MRT), positron emission tomography (PET) to single 
photon emission computed tomography (SPECT).  In addition with contrast agents, these 
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methods allow a precise imaging diagnosis. Nevertheless, stereotactic biopsies and liquor 
diagnostics are performed to fully diagnose a glioma. 
 
1.3.3. Pathology of glioma 
As glioma derives from healthy cells in the brain, they hardly express antigens which can 
be targeted by the immune system of the patient (Li et al., 2008). 
Nevertheless, the immune system fights tumor cells after transition, a resistant polulation 
remains and forms a resistant tumor mass (Dunn et al., 2002). 
Gliomas developed several mechanisms to overcome the anti-tumor response of the 
immune system (Fig. 1.7).  
 
 
Fig. 1.7: Overview of immune response suppression by glioma cells. Glioma cells secrete factors such as 
TGF-β and IL-10 which suppress the interaction of and immune answer mediated by T cells and antigen 
presenting cells (Prins et al., 2004) 
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Tumor cells in glioma are known to express a variety of immune-suppressive molecules 
like IL-10, prostaglandin E2 or TGF-β (Wrann et al., 1987; Wiendl et al., 2002; 
Wischhusen et al., 2002). The secretion of these molecules leads to a local 
immunosuppression as well as to a systemic immunodeficiency via impeding microglia 
and T cell activation (Platten et al., 2001). TGF-β inhibits antigen presentation of 
dendritic cells and other antigen presenting cells, and interferes with natural killer (NK) 
cells. Furthermore, it inhibits the activation and differentiation of cytotoxic T cells 
(Weller and Fontana, 1995). Thus, tumor specific antigens are lost and the tumor cells are 
capable of hiding from the immune system (Vega et al., 2008). It was shown by Hao and 
colleagues that pro-inflammatory cytokines such as IFN-γ, TNF-α or IL12 and their 
corresponding receptors are barely expressed in the tumor residuum (Hao et al., 2002). 
The sum of these immune-suppressive reactions even results in a variety of healthy cells 
such as microglia, lymphocytes or endothelial cells which supply the tumor with nutrients 
and oxygen (Badie and Schartner, 2001; Watters et al., 2005). 
 
1.3.4. Mutations in gliomas 
In tumor cells, a wide variety of mutations can be found. The most prominent ones are 
mentioned below. 
The gene p53, also called the tumor suppressor gene, has a prominent function in cell 
cycle control, DNA repair and apoptosis (Kern et al., 1991). Mutations causing deletion 
or alterations of this gene are the most common ones in human gliomas, causing 
increased cell proliferation and angiogenesis (Watanabe et al., 1997).  
Another mutation found especially in glioblastomas with a prevalence of 50% are 
amplifications of the epidermal growth factor receptor (EGFR)-gene (Zhang et al., 2008), 
which codes for a receptor involved in the stimulation of cell division. Overexpression or 
alteration causing isoform proteins lead to an increased activity of that protein. Therapies 
aiming at EGFR were found to sensitize tumor cells to chemotherapy and radiotherapy 
(Slamon et al., 2001). 
Phosphatase and tensin homolog (PTEN) acts as a tumor suppressor gene through its 
phosphatase properties, which is involved in regulation of the cell cycle (Chu et al., 
2004). Mutation in this protein leads to an immense increase in cell division and is found 
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in most gliomas. 
Additionally, loss of heterozygosity (LOH) is a frequent gene alteration in 60-90 % of 
glioblastoma. This mutation is closely linked to a poor survival rate and is most likely 
one of the key feature in glioblastoma development (von Deimling et al., 1992). 
During the last years, so called tumor stem cells were described for several glioma types 
(Ignatova et al., 2002; Singh et al., 2003; Yuan et al., 2004; Taylor et al., 2005). These 
cells share properties with neural stem cells. This fact indicates that gliomas may rise 
from those cells. Further evidence for this hypothesis was found in mice experiments, as 
a mutation of p53 in cells of the subventricular zone (SVZ) leads to glioma formation 
(Uhrbom et al., 2002). 
 
1.3.4. Therapy of glioma 
Treatment of glioma is still a major clinical challenge and up to now no curative 
treatment is at hand. Generally, the therapy of choice depends on several factors like 
location, cell type and grade of the tumor. Mostly, gliomas are treated with a combination 
of the following three approaches. Many studies aim at the improvement of the current 
treatments (Valtonen et al., 1997; Chan et al., 2005; Reardon et al., 2006). 
One of the main treatments of glioma is the surgical therapy. A lot of studies showed that 
the extent of the tumor resection closely correlates with the survival time of the patient 
(Soffietti et al., 1989; Jeremic et al., 2003; Keles et al., 2004). The patient not only 
benefits from the removal of tumor tissue, but also from the release of intercranial 
pressure, which improves further therapeutic approaches. Nevertheless, brain surgery is 
not capable of removing all infiltrating tumor cells which cause glioma reformation. 
Radiotherapy is another standard therapy for the treatment of glioma. Nowadays, for 
smaller gliomas stereotactic radiotherapy is used, in which a precise application of 
radation to the glioma is possible. But, in respect to long term survival, no effect of 
radiotherapy alone was found in case of grade II gliomas (Karim et al., 2002).   
Chemotherapy aims at the impairment of cell division, which mostly affects fast-dividing 
cells like tumor cells. Therefore, a variety of cytotoxic chemotherapeutics is used in 
established combinations and cycles. One of the biggest disadvantages of this therapy is 
that it not only affects tumor cells but also healthy dividing cells as well. This leads to 
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hair loss and damage of the intestinal epithelium. 
Experimental therapies are mostly located on a molecular level, leading to so called 
molecular targeted therapy approaches. These approaches aim at the cancer specific 
signal cascades and molecules to influence proliferation, invasion and angiogenesis 
(Krause et al., 2005; Adjei et al., 2005). One of the most promising targets is TGF-β. 
Encouraging data was obtained using a TGF-β antisense oligonucleotide for the treatment 
of glioblastoma (Schlingensiepen et al., 2006). Animal experiments and in vitro data 
endow this finding (Jachimczak et al., 1996). 
Another possible candidate is the platelet derived growth factor (PDGF) receptor. Upon 
inhibition with imatinib the tumor growth rate decreases and complete remission could be 
seen in some patients (Dresemann et al., 2005). 
A promising approach is the antiangiogenetic therapy, which aims at the inhibition of 
tumor neovascularization. So far, over 70 compounds have been tested, of which the most 
promising are Cediranib and Bevacizumab (Batchelor et al., 2007; Vredenburgh et al., 
2007). 
Studies about immunotherapy involving cytokines like IL-2 or interferons did not result 
in proof of effectiveness, additionally leading to immense toxic and neurotoxic side-
effects (Merchant et al., 1988; Albert et al., 1998). Another approach in this field is the 
active specific immunotherapy which includes the in vivo induction of tumorspecific 
cytotoxic T lymphocytes. Upon induction, these cells might trigger apoptosis of tumor 
cells (Kägi et al., 1994). 
A variety of genetherapy-strategies has been examined in regard to malign gliomas. 
Mostly, adenoviral and retroviral vectors are used to deliver therapeutical genes into the 
glioma site. Examples for that are the oncolytic genetherapy, p53-genetransfer or IFN-β 
genetransfer (Mineta et al., 1995; Lang et al., 2003; Yoshida et al., 2004). 
A therapeutic effect was demonstrated in vivo by bone marrow derived cells expressing 
thymidine kinase of herpes simplex virus (HSV-tk) through bystander-mediated glioma 
cell killing after gancylovir application (Miletic et al., 2007).  
In summary, gene therapy seems to be the most promising approach to conquer malignant 
glioma in a safe and reliable fashion. 
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1.3.5. Role of microglia  
The properties of microglia can both fight or support tumor cells in the CNS and once 
more show their double-edged nature. 
Microglia and macrophages are known to be attracted by and to infiltrate the glioma via 
the fractalkine pathway (Umemura et al., 2008; Held-Feindt et al., 2010) and are the most 
commonly found immune cells in the tumor residuum (Graeber et al., 2002). Recruitment 
of microglia is mediated through a variety of cytokines such as CXCL1, CCL2 and 
colony stimulating factor 1 (CSF-1) (Held-Feindt et al., 2010; Lamagna et al., 2006). 
These tumor-infiltrating microglial cells obtain an immuno-suppressive phenotype and 
promote production of TGF-β via an autocrine loop (Umemura et al., 2008). In addition 
to the immunosuppressive cytokine milieu provided by the glioma cells, this effect leads 
to T cell tolerance and inactivation of tumor targeted immune responses (Carpentier et 
al., 2006).  It has been demonstrated that tumor-associated macrophages (TAMs) are 
polarized into the alternatively activated M2 subtype which supports tumor infiltration 
and growth (Martinez et al., 2008; Mantovani et al., 2001). TAMs secrete anti-
inflammatory cytokines like IL-10, IL-23 and therefore establish an immunosuppressive 
environment (Badie and Schartner, 2001; Wu et al., 2010). They have also been shown to 
express MMPs which enhance tumor progression through degradation of extra-cellular-
matrix (ECM) (Rao, 2003). Via secretion of EGF, microglia are also capable of 
enhancing tumor angiogenesis and proliferation (Lafuente et al., 1999). 
Microglia have also been described to have detrimental effects on glioma cells. After pro-
inflammatory stimuli, activated microglia of the M1 subtype can secrete molecules which   
inhibit glioma growth (Nickles et al., 2008). Mora et al observed activated microglia that 
can induce autophagy-dependent death of glioma cells (Mora et al., 2009). As microglia 
are phagocytic cells, they are also capable of decreasing glioma cell number through 
phagocytosis. It has been stated that macrophages are able to phagocyte glioma cells in 
absence of apoptosis of glioma cells (Fadeel et al., 2004).  
In addition to direct functions of microglia in fighting glioma, they are also involved in 
recruiting NK cells, which play a pivotal role in tumor rejection via induction of tumor 
cell apoptosis. In the CNS, attraction of NK-cells is for instance mediated by CX3CL1 
secreted by microglia (Huang et al., 2006). 
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2. Materials and Methods 
 
2.1. Materials 
 
2.1.1. Buffers and solutions 
10x (0.125 M) Phosphate buffered saline (PBS), pH 7.3 
0.007 M NaH2PO4*H2O  (Roth, Germany) 
0.034 M NaH2PO4*7H2O (Roth, Germany) 
0.6 M NaCl (Roth, Germany) 
ad 1 liter ddH2O (Roth, Germany) 
 
10x Annexin binding buffer 
 100 mM HEPES 
 1,4 M NaCl 
 25 mM CaCl2 
 
10x Tris-Boric Acid-EDTA (TBA) buffer 
1.78 M Tris-Base (Roth, Germany) 
1.78 M Boric Acid (Sigma, Germany) 
0.04 M Ethylenediaminetetraacetic Acid (EDTA) (Roth, Germany) 
ad 2 liter ddH2O (Roth, Germany) 
 
1 % Agarose gel 
0.5 g Agarose (Biozym, Germany) 
1.25 µl Ethidium Bromide (Roth, Germany) 
50 ml TBE (1x)  
 
4% Paraformaldehyd (PFA), pH 7.3 
20 g PFA (Sigma, Germany) 
30 ml NaOH (Roth, Germany) 
50 ml PBS (10x)  
ad 1 liter ddH2O  (Roth, Germany) 
 
6x Loading buffer 
0.5 M EDTA (Roth, Germany) 
60 % Sucrose (Roth, Germany) 
0.04 % Bromphenol Blue (Sigma, Germany) 
0.04 % Xylene Cyanole (Sigma, Germany) 
2 % vol/vol Ficol-400 (Bio-Rad, Germany) 
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Moviol 
4.8 g Moviol (Kremer Pigmente, Germany) 
12 g Glycerol (Sigma, Germany) 
12 ml ddH2O  (Roth, Germany) 
24 ml Tris buffer 0.2 M (Roth, Germany) 
1.32 g DABCO (Sigma, Germany) 
 
TRIS 
 12.1 g Trizma Base (Sigma, Germany) 
 18.0 g Sodium Chloride (Roth, Germany) 
88 ml Hydrochloric Acid 1 M (Roth, Germany) 
ad 2 liter ddH2O (Roth, Germany), adjust to pH 7.4 
 
Reverse transcription (RT) mix 
5 µg total ribonucleic acid (RNA)  
1 µl Hexanucleotide Mix (10X) (Roche, Germany) 
1 µl Deoxynucleotide triphosphate (dNTP) mix (10mM) (Sigma, Germany) 
2 µl Dithiothreitol (DTT) mix (10 mM) (Invitrogen, Germany) 
4 µl 5X RT 1st Strand Buffer (Invitrogen, Germany) 
1 µl RT enzyme (200 U/ml) (Invitrogen, Germany) 
ad 20 µl ddH2O  (Roth, Germany) 
 
Quantitative real time-polymerase chain reaction (qRT-PCR)-mix 
3 µl Complementary Deoxyribonucleic Acid (cDNA) (200 ng/µl)  
1 µl SYBR Green Master Mix (2x) (Applied Biosystems, USA) 
2 µl Primer mix (10 pmol/µl)  
10.5 µl ddH2O (Roth, Germany) 
 
2.1.2. Cell culture media and reagents 
ES medium 
Dulbecco’s modified Eagle's medium (DMEM) 4.5 g/l D-glucose (Gibco, 
Germany) 
2 mM GlutaMAX (Gibco, Germany) 
1 mM Sodium-Pyruvate (Gibco, Germany) 
0.1 mM Non-essential-amino acids (Gibco, Germany) 
0.05 mM 2-Mercaptoethanol (Gibco, Germany) 
15 % vol/vol Fetal Calf Serum (FCS) (Gibco, Germany) 
1 µg/l Leukemia Inhibitory Factor (LIF) (Chemicon, USA) 
 
Basal medium 
Basal Medium Eagle (BME) (Gibco, Germany)  
10 % vol/vol FCS (Gibco, Germany) 
1 % vol/vol D-glucose (Sigma, Germany) 
2 mM L-glutamine (Gibco, Germany) 
100 µg/ml penicillin/streptavidin (pen/strep) solution (Gibco, Germany) 
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Differentiation medium 
DMEM 4.5 g/l D-glucose (Gibco, Germany) 
2 mM GlutaMAX (Gibco, Germany) 
1 mM Sodium-pyruvate (Gibco, Germany) 
0.2 mM Non-essential-amino acids (Gibco, Germany) 
0.05 mM 2-Mercaptoethanol (Gibco, Germany) 
15 % vol/vol FCS (Gibco, Germany) 
 
Glioma medium 
DMEM/F12 (Gibco, Germany) 
10 % vol/vol FCS (Gibco, Germany) 
100 µg/ml pen/strep solution (Gibco, Germany) 
 
ITSFn medium 
DMEM/F12 (Gibco, Germany) 
25 µg/ml Insulin (Sigma, Germany) 
30 nM Sodiumselenite (Sigma, Germany) 
50 µg/ml Transferrin (Sigma, Germany) 
5 µg/ml Fibronectin (Sigma, Germany); (add freshly before using medium) 
 
MEF medium 
DMEM 4.5 g/l D-glucose (Gibco, Germany) 
2 mM L-glutamine (Gibco, Germany) 
1 mM Sodium-Pyruvate (Gibco, Germany) 
0.1 mM Non-essential-amino acids (Gibco, Germany) 
10 % vol/vol FCS (Gibco, Germany) 
 
N2 medium 
DMEM/F12 (Gibco, Germany) 
1 x N2 supplement (Gibco, Germany) 
0.48 mM L-glutamine (Gibco, Germany) 
5.3 µg/ml D-glucose (Sigma, Germany) 
100 µg/ml pen/strep solution (Gibco, Germany) 
 
Neuronal medium 
Basal medium eagle (Gibco, Germany) 
1 % vol/vol FCS (Gibco, Germany) 
1 % vol/vol D-glucose solution (Sigma, Germany) 
2 % vol/vol B27 supplement (Gibco, Germany) 
 
 
 
 
 
 
 
  Material and Methods 
 32
2i medium 
 50 ml DMEM/F12 (Gibco, Germany) 
 50 ml Neurobasal Medium (Gibco, Germany) 
 0.5 ml N2 (100x , Gibco, Germany) 
1 ml B27 (50x, Gibco, Germany) 
0.5 ml GlutaMax (100x Gibco, Germany) 
0.5 ml BSA (5 mg/ml) 
50 µl Insulin (20 mg/ml) 
200 µl β-Mercapthoethanol (Gibco, Germany) 
1 µg/l Leukemia inhibitory factor (LIF) (Chemicon, USA) 
10 µl PD0325901 (10mM, Axon Medchem) 
30µl CHIR99021 (10mM, Axon Medchem) 
 
2.1.3. Other reagents 
• 5x RT 1st Strand Buffer (Invitrogen, Germany) 
• Ampicilin (Sigma, Germany) 
• Alkaline phosphatase Detection Kit (Millipore, Germany) 
• Annexin, biotinylated (Sigma, Germany) 
• Bovine serum albumin (BSA) (Sigma, Germany) 
• Corbitbalm (Hecht, Germany) 
• CX3CL1, recombinant mouse (R&D, Germany)  
• Dimethylsulfoxide (DMSO) (Sigma, Germany) 
• Endofree Plasmid Maxiprep (Qiagen, Germany) 
• Ethanol (Roth, Germany)  
• Fibroblast growth factor (FGF) 2, recombinant human (R&D, Germany) 
• Fibronectin from bovine plasma (Sigma, Germany) 
• Fluoresbrite Polychromatic Red microspheres 1.0 µm (Polyscience, USA)  
• G418 antibiotics (Sigma, Germany) 
• Gelatin (Fluka, Germany)  
• Granulocyte macrophage-colony stimulating factor (GM-CSF), 
recombinant mouse (Invitrogen, Germany)  
• Hexanucleotide Mix (10x) (Roche, Germany) 
• IFN-γ, recombinant mouse (R&D, Germany)   
• Incomplete Freund’s adjuvant (Difco, USA)  
• Isopropanol  (Sigma, Germany) 
• Laminin, natural mouse (Invitrogen, Germany) 
• Lysogeny broth (LB) agar and LB media (Fluka, Germany)  
• Lipopolysaccharides (LPS ; Sigma, Germany)  
• LookOut® Mycoplasma PCR Detection Kit (Sigma, Germany)  
• MOG35-55 (MEVGWYRSPFSRVVHLYRNGK) (Charité, Berlin, Germany)  
• Mycobacterium Tuberculosis H37Ra (List Biological Laboratories,USA)  
• Normal goat serum  (nGS) (Sigma, Germany) 
• Neurotrophin3,recombinant (R&D, Germany) 
• Okadaic acid potassium salt (Sigma, Germany)  
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• Opti-MEM (Gibco, Germany) 
• PBS (1x) (Gibco, Germany) 
• Pertussis toxin (List Biological Laboratories,USA)  
• Puromycin (PAA, Germany) 
• Poly-L-lysine (PLL) (Sigma, Germany) 
• Reverse transcriptase hexamer (Roche, Germany) 
• RNeasy Mini Kit (Qiagen, Germany) 
• RNAse free DNAse Kit (Qiagen, Germany) 
• SuperScript® III Platinum® Two-Step qRT-PCR Kit (Invitrogen, Germany) 
• SYBR Green Master Mix (2x) (Applied Biosystems, UK)  
• TritonX-100 (Sigma, Germany) 
• Transferrin bovine (Sigma, Germany) 
• Trypsin-EDTA 0.25 % (Gibco, Germany) 
 
2.1.4. Vectors 
• PLL- phosphoglycerate kinase (PGK) green fluorescent protein (GFP)-
Neomycine-resistance  (received from Dr. Isabella Napoli, Bonn, Germany) 
• PLL-PGK NT3-Neomycine-resistance  
• PLL3.7 vectors (provided by L. van Parijs, MIT, Cambridge, MA) 
• Packaging plasmid PLP1 ViraPower ™ (Invitrogen, UK) 
• Packaging plasmid PLP2 ViraPower ™ (Invitrogen, UK) 
• Packaging plasmid PLP3 ViraPower ™ (Invitrogen, UK) 
• TRC hairpin-pLKO.1-puro vector (Broad Institute TRC, Cambridge, USA/ Prof. 
Dr. Hornung, Institute of Clinical Chemistry and Pharmacology, Bonn, Germany) 
• Mission pLKO.1-puro Non-Mammalian shRNA Control Plasmid DNA (Sigma, 
Germany) 
 
2.1.5. Cell lines 
ES-C57BL/6-ATCC BL6 (ATCC, Germany) 
GL261 (Hertie-Institute for clinical neurology, Germany)  
SMA560 (Hertie-Institute for clinical neurology, Germany)  
Human Embryonic Kidney (HEK) 293 cells cells (Invitrogen, Germany) 
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2.1.6. Antibodies 
Primary antibodies for immunocytochemistry  
Antibody Host Dilution Supplier 
Arginase goat 1:100 Santa Cruz Biotech, USA 
β-tubulin-III mouse 1:500 Sigma, Germany 
CD16/32 rat 1:500 BD Biosciences, Germany 
CD45 rat 1:500 BD Biosciences, Germany 
CD68 rat 1:500 AbD Serotec, USA 
CD86 rat 1:500 BD Biosciences, Germany 
CD206 goat 1:100 R&D Systems, Germany 
GFAP rabbit 1:1000 DAKO, USA 
Iba1 rabbit 1:500 Wako, Germany 
iNOS rabbit 1:500 BD Biosciences, Germany 
Nestin mouse 1:200 Millipore, Germany 
NT3 rabbit 1:100 Santa Cruz, USA 
Oct 4 mouse 1:250 Santa Cruz, USA 
Sox2 rabbit 1:250 Abcam, USA 
SSEA1 mouse 1:80 Abcam, USA 
GAP43 rat 1:200 DAKO, USA 
 
Secondary antibodies for immunocytochemistry  
Antibody Host Directed against Dilution Supplier 
Alexa488 goat  anti mouse 1:500 Invitrogen, Germany 
Alexa488 goat anti rabbit 1:500 Invitrogen, Germany 
Alexa488 goat  anti rat 1:500 Invitrogen, Germany 
Cy3 goat anti mouse 1:500 Dianova, Germany 
Cy3 goat anti rabbit 1:500 Dianova, Germany  
Cy3 goat anti rat 1:500 Dianova, Germany 
 
Primary antibodies for flow cytometry  
Antibody Host Dilution Supplier 
CCR2 mouse 1:80 Abcam, USA 
CD11b-biotinylated rat 1:200 BD Biosciences, Germany 
CD11c- biotinylated hamster 1:200 BD Biosciences, Germany 
CD16/32 rat 1:100 BD Biosciences, Germany 
CD29 rat 1:200 BD Biosciences, Germany 
CD34 rat 1:200 BD Biosciences, Germany 
CD36- biotinylated mouse 1:200 BD Biosciences, Germany 
CD45- biotinylated rat 1:200 BD Biosciences, Germany 
CD49- biotinylated rat 1:200 BD Biosciences, Germany 
CD68- biotinylated rat 1:50 AbD Serotec, Germany 
CD80- biotinylated rat 1:200 BD Biosciences, Germany 
CD86- biotinylated rat 1:200 BD Biosciences, Germany 
CD115- biotinylated sheep 1:40 R&D Systems, Germany 
CD117/cKit- biotinylated rat 1:200 BD Biosciences, Germany 
CD133- biotinylated rat 1:200 eBioscience, USA 
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CX3CR1 rabbit 1:200 ProSci Inc, USA 
F4/80- biotinylated rat 1:100 AbD Serotec, Germany 
Ly6G- biotinylated rat 1:50 Abcam, USA 
MHC II- biotinylated rat 1:200 BD Biosciences, Germany 
SiglecH- biotinylated rat 1:200 Hycult Biotech. Germany 
Trem2 rat 1:200 BD Biosciences, Germany 
Isotype IgG1 rat 1:200 BD Biosciences, Germany 
Isotype IgG2 rat 1:200 BD Biosciences, Germany 
Isotype IgA mouse 1:200 BD Biosciences, Germany 
 
Secondary antibodies for flow cytometry secondary antibodies 
Antibody Host Directed against Dilution Supplier 
PE goat Streptavidin 1:500 Jackson Immuno, USA 
PE goat anti rat 1:500 Jackson Immuno, USA 
PE goat anti rabbit 1:500 Jackson Immuno, USA 
 
2.1.7. Other staining reagents 
4',6-diamidino-2-phenylindole (DAPI) (Sigma, Germany) 
PKH26, red fluorescent (Sigma, Germany) 
 
2.1.8. Primer for qRT-PCR 
Oligonucleotides obtained from Eurofins MWG  
Name Forward sequence Reverse sequence 
Arginase  CAG AAG AAT GGA AGA GTC AG CAG ATA TGC AGG GAG TCA CC 
CCL2 CAG GTC CCT GTC ATG CCT CT GGG ATC ATC TTG CTG GTG AA 
CX3CL1 TGG TGA TCC AGA TGC TTC AT TGC TCA TCC GCT ATC AGC TA 
CXCL9 CTT CCT GGA GCA GTG TGG AG TGT TGC AAT TGG GGC TTG 
CXCL10 CAT CCA CCG CTG AGA GAC AT CTC AGA CCC AGC AGG ATG AG 
Fizz CTG GTG AGT TCG GGT CAG CTC 
TGT 
CAG TAT TCA CTG GGA CCA TCA 
GCT G  
GAPDH ACA ACT TTG GCA TTG TGG AA GAT GCA GGG ATG ATG TTC TG 
IL-1β ACA ACA AAA AAG CCT CGT GCT G CCA TTG AGG TGG AGA GCT TTC A 
IL-10 AAG GAC CAG CTG GAC AAC AT TCT CAC CCA GGG AAT TCA AA 
NOS2 AAG CCC CGC TAC TAC TCC AT GCT TCA GGT TCC TGA TCC AA 
NT3 AAA TAG TCA CAC GGA TGC CA GGC AAA CTC CTT TGA TCC AT 
SiglecH GTG ACA GAC CTC ACT CAC AGC CC GGT CGT GGG GCC CAG GGA TA 
TGF-β CAA TTC CTG GCG TTA CCT TG GCT GAA TCG AAA GCC CTG TA 
TNF-α TCT TCT CAT TCC TGC TTG TGG AGG GTC TGG GCC ATA GAA CT 
Ym1 CAT TCA GTC AGT TAT CAG ATT CC AGT GAG TAG CAG CCT TGG 
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2.1.9. Consumables 
• 0.22 µm pore size filter stericup (Millipore, USA) 
• 10 µl, 100 µl, 1000 µl pipette tips (Eppendorf, Germany) 
• 10 ml syringes (Braun, Germany) 
• 175 cm2 tissue cell culture flask (Sarstedt, Germany) 
• 5 ml disposable plastic pipette (Costar, Germany)   
• 6-well-plate (Cellstar, Germany)   
• 75 cm2 tissue cell culture flask (Sarstedt, Germany) 
• 8.0 µm Culture Plate Inserts 12 mm Diameter (Millipore, Germany)  
• 10 ml disposable plastic pipette (Costar, Germany) 
• 15 ml tubes (Greiner, Germany)  
• 24-well-plate (Greiner bio-one, Germany)  
• 48-well-plate (Greiner bio-one, Germany)  
• 25 ml disposable plastic pipette (Costar, Germany) 
• 50 ml plastic tubes (Sarstedt, Germany) 
• 5 ml polystyrene round-bottom tubes (BD Falcon, Germany) 
• Bottle top filters, 0.25µm pore (Milipore, Germany) 
• Cell scraper (Sarstedt, Germany)  
• Cell strainer (BD Falcon, Germany)  
• Cotton buds (Roth, Germany)  
• Chamber slides (Nunc, Germany) 
• Cryovials (VWR, Germany) 
• Erlenmeyer flask, 250 ml (Schott-Duran, Germany)  
• Glass beads 5 mm (Roth, Germany) 
• Glass cover slides 24x24 mm (VWR, Germany)  
• Glass needles, pulled and polished, 50-100 µm (Hofheim, Germany) 
• Glass pasteur pipettes (Brand, Germany) 
• Injection needles (Braun, Germany) 
• Lab – Tek Chamber Slide w/Cover Permanox Slide Sterile 4 Well (Labomedic, 
Germany) 
• MicroAmp® 96- & 384-Well Optical Adhesive Film (Applied Biosystems, USA)  
• MicroAmp optical 96 well plate (Applied Biosystems, USA)  
• PCR tubes (Biozym Diagnostics, Germany) 
• Petri dishes 100x15 mm (BD Falcon,Germany)  
• Tissue culture dish 100x20 mm (Sarstedt, Germany)  
• Tissue culture dish 60x15 mm (Sarstedt, Germany) 
• Tissue culture dish 150x20 mm (TPP, Germany) 
• Tissue Tek (Sakura, USA) 
• Tubes 1.5 ml (Eppendorf, Germany) 
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2.1.10. Equipment 
• Axioskop 2 (Zeiss, Germany) 
• Axiovert 40 CFL (Zeiss, Germany) 
• BD FacsCalibur (BD Bioscience)  
• Biofuge Fresco (Heraeus, Germany) 
• Canon Powershot G9 (Canon) 
• Centrifuges Sorvall Discovery 90SE (Hitachi, Germany) 
• Cryostat Microtom HM560 (Microm Int., Germany) 
• Electrophoresis gel chambers (Biomed Analytik GmbH, Germany) 
• Eppendorf Mastercycler epgradient S (Eppendorf Germany) 
• Fluoview1000 Confocal microscope (Olympus,Germany) 
• Freezer -80°C Herafreeze (Heraeus, Germany) 
• Hamilton syringe (Hamilton, USA) 
• Hot bead sterilizer (FST, Germany) 
• Incubator HeraCell 240 (Heraeus Germany) 
• Laminar air flow workbench Herasafe (Heraeus, Germany) 
• Megafuge, 1.OR. (Heraeus, Germany) 
• Microm HM560 cryostat (Microm, Germany)  
• Neubauer chamber (Brand, Germany) 
• Power supply (Amersham Bioscience, Germany) 
• RS 2000 X-ray source (Rad Source Technologies, USA)  
• Surgical instruments (F.S.T,Germany) 
• Thermocycler T3 (Biometra, Germany) 
• Vortex 2X (Velp Scientifica, Germany) 
 
2.1.11. Software / Databases 
• Openlab4.0.1 (Improvision, Germany) 
• CorelDRAW Graphics Suite 11 (Corel, Germany) 
• EndNote X1 (Thomson ISI ResearchSoft, USA) 
• Microsoft Office (Microsoft, USA) 
• Olympus FluoView1.4 (Olympus, Germany) 
• SDS 2.2.2 (Applied Biosystems, USA) 
• Cellquest Pro (BD Biosciences, USA) 
• FlowJo 6.4.7 (Tree Star, USA) 
• KaleidaGraph 4.0 (Synergy, USA) 
• Graph Pad Prism 5, (Graph Pad Software, USA) 
• Axiovision 4.6.3 (Carl Zeiss Imaging Solutions, Germany) 
• ImageJ 1.39u (NIH, USA) 
• NCBI gene bank 
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2.1.12. Anesthethics  
• Ketamin (Ketanest, Pfizer, Germany) 
• Xylazin (Rompun, Bayer, Germany) 
 
Before perfusion and for immunization for EAE experiments, animals were anesthesized 
with Ketamin/Xylazin i.p. (Ketamin 80 mg/kg and Xylazin 16 mg/kg). 
 
2.1.13. Mice 
C57BL/6 mice were obtained from Charles River (Sulzfeld, Germany). All mice were 
kept and bred under pathogen free conditions in a 12 hour light/12 hour dark cycle with 
access to food and water ad libitum in the animal facility.   
 
 
 
  Material and Methods 
 39
2.2. Methods 
 
2.2.1. Generation of embryonic stem cell lines 
For generation of ESC lines, C57BL/6 mice were used. Females were superovulated with 
i.p. injection of 5 international units (IU) of pregnant mare serum gonadotrophin (PMSG) 
at noon and 5 IU of human Chorionic Gonadotropin (hCG) 46 hours later. Breeding pairs 
were set up and plug-positive females were isolated. Females were sacrificed at day 3.5 
post coitus and uteri were flushed with PBS to isolate blastocysts. Blastocysts were 
seeded to irradiated mouse embryonic fibroblast (MEF) cells in 48-well plates in 2i 
medium mixed 1:1 with ES medium. Two days later, half of the medium was replaced. 5 
days post isolation, cells were trypsinized and transferred to a 24-well plate with MEF 
layer. Medium was replaced every day. After 10 to 12 days, primary ESC colonies were 
frozen down and expanded. 
 
2.2.2. Generation of embryonic stem cell derived microglia 
The murine ESC line ES-C57BL/6-ATCC (BL6) was used for the differentiation into 
ESdM. The differentiation protocol was obtained by modifications of a neuronal 
differentiation method (Lee et al., 2000). The protocol consists of five steps: 
(i) cultivation of ESC, (ii) formation and differentiation of embryoid bodies (EBs), (iii) 
differentiation into neuroectodermal lineage and isolation of myeloid precursor cells, (iv) 
differentiation into microglial precursor cells and (v) cultivation of ESdM.  
Undifferentiated ESC were kept in culture in presence of LIF containing ES medium on a 
MEF layer. They were trypsinized and cultured on gelantin-coated tissue culture dishes 
for one day in ES medium with LIF. For EB formation, cells were dissosciated and plated 
onto bacterial culture dishes in Differentiation medium. After 4 days, the resulting EBs 
were plated to gelatin coated cell culture dishes. Two days later, selection of nestin-
positive cells was initiated using ITSFn medium. After 6 days, cells were expanded in N2 
medium containing 1 µg/ml laminin and 5 ng/ml bFGF. Microglial differentiation was 
triggered by removal of bFGF after 6 days. Laminin was withdrawn after 6 additional 
days. Three weeks after growth factor withdrawal, ESdM could be isolated by manual 
picking. 
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 2.2.3. Maintenance and subpolarization of cell lines 
ESdM were kept in N2 medium in 5% CO2 at 37°C. Upon 80 % confluency, cells were 
splitted with a cell scraper. ESdM could be frozen slowly in N2-medium supplemented 
with 10 % DMSO and 50 % FCS. 
For subpolarization of ESdM, cells were treated with 100 U/ml IFN-γ and 5 ng/ml LPS 
for 24 hours for M1 or 20 ng/ml IL-4 for 48 hours for M2 subpolarization.  
SMA560 and GL261 glioma cells were kept in glioma medium at 37°C and 5% CO2. 
Upon confluency, cultures were splitted using Trypsin. 
 
2.2.4. Isolation of primary neurons and regeneration assay 
Primary neurons were isolated from 15 day old C57BL/6J mice embryos (Gorlovoy et 
al., 2009). They were cultured in neuronal medium in PLL coated chamber slides at 37°C 
and 5% CO2. For the regeneration assay, medium was supplemented with different 
amounts of ESdM culture supernatant, PBS or 10 ng/ml recombinant NT3 and incubated 
for 48 h. Immunocytochemistry was carried out with antibodies directed against growth 
associated protein (GAP) 43 and Iba1. 
 
2.2.5. Isolation of primary microglia 
Primary microglia were obtained from brains of postnatal (day 3 or 4) C57BL/6 mice 
(Takahashi et al., 2005). Briefly, meninges were removed and dissociated by trituration. 
Cells were cultured in basal medium for 2 weeks to form a confluent mixed glial 
monolayer. To isolate microglial cells, cultures were shaken on a rotary shaker for 3 h at 
350 rpm. Detached microglia were seeded on PLL coated culture dishes in N2 medium. 
 
2.2.6. Lentiviral transduction of cells 
For lentiviral transduction of ESdM (GFP and NT3) and SMA560 cells (GFP), PLL3.7 
vectors were used. Vectors contained a neomycine-resistance gene for selection of 
successfully transduced cells. GFP and NT3 were cloned under control of a pgk-promoter 
in the backbone. Calcium-phosphate precipitates were prepared with 25 µg pLP1, 12.5 µg 
pLP2 and 15 µg pLP3 (Invitrogen) and 25 µg lentiviral vector plasmid of interest in 1.125 
ml water and 125 µl CaCl2 (2.5 M). Precipitates were then applied to HEK293FT cells in 
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MEF medium (5% FCS). After 48 and 72 h, the supernatant was collected, filtered and 
transferred to target cells.  Two days post transduction, cells were selected using 250 
µg/ml G418 for GFP and NT3 vectors and with 20 µg/ml Puromycin for shRNA knock-
down vectors. 
The following plasmids were used for generating knockdown ESdM: 
siglech: TRCN0000068083, Target sequence: 5’-GCCCAAATTAACATTAGAGAA-3’ 
trem2: TRCN0000068094 Target sequence:  5’-GTCATGTACTTATGACGCCTT-3’ 
Knock-down plasmids for sialic acid binding immunoglobulin -like lectin H (SiglecH) 
and Trem2 were generous gifts from Prof. Dr. Veit Hornung, University of Bonn. Non-
target shRNA Control Plasmid (Sigma, Germany) was used as control for the knock-
down experiments. 
 
2.2.7. Immunocytochemistry of cultured cells 
For immunocytochemistry, cells were fixed with 4% PFA for 10 min, blocked with 10x 
BSA containing 5% nGS (for 30 min and stained with various antibodies (see 2.1.6) 
overnight. 
Secondary antibodies were applied for 30 min, cells were washed with PBS and finally 
stained with DAPI for 30 s and covered with Moviol. Images were taken with a 
fluorescence microscope (Axioskop2, Zeiss) or a confocal microscope (Fluoview 
FV1000, Olympus). 
 
2.2.8. Flow cytometry analysis 
ESdM were collected using a cell scraper. Fc-receptor blockade was performed with a rat 
monoclonal antibody against CD16/CD32. Cells were stained with various antibodies 
(see 2.1.6) for 60 min on ice. After washing with PBS, samples were incubated with 
secondary antibody for 30 min on ice in darkness. Isotype-matched controls and non-
stained cells were used as negative controls. Analysis was performed with a 
FACSCalibur flow cytometer and FlowJo Software. 
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2.2.9. Analysis of cytokine gene transcripts by qRT-PCR 
RNA was isolated according to the manual using the RNeasy Mini Kit. Afterwards, 
reverse transcription was performed with SuperScript III reverse transcriptase and 
hexamer random primers. For quantitative real time (RT)-PCR, 600 ng of cDNA, SYBR 
Green PCR Master Mix and specific oligonucleotides were used according to the 
following conditions: 
 
 
 
The quantitative RT-PCR was carried out using the Eppendorf epgradient S Mastercycler 
with the following programme: 
 
Cycle number Denature Anneal Extend 
1 95°C for 10 min - - 
2-40 95°C for 10 s 60°C for 30 s 72°C for 30 s 
 
Amplification specificity was confirmed via analysis of melting curves. Quantification 
was performed using the deltadelta-CT method. 
 
2.2.10. RNA Microarray 
For RNA microarray, RNA was isolated according to the manual using the RNeasy Mini 
Kit from Qiagen. 1 mg of RNA of three ESdM or primary microglia cultures was used. 
Microarray analysis was performed at the LIMES institute, Bonn, Germany by the 
working group of A. Staratscheck-Jox using the Ambion Illumina system. 
 
2.2.11. Phagocytosis assay 
For analysis of phagocytosis capacity of the ESdM, a phagocytosis assay with labeled 
microsphere beads was performed. 1x105 cells were seeded to each well of a 6-well-plate 
in N2-medium. For stimulation of the cells, 500 ng/ml LPS were added for 24 h. 
Component Amount per reaction Final 
SYBR green mix (2x) 12.5 µl 1 x 
cDNA (200 ng/µl) 3 µl 600 ng 
Primer (10 pmol/µl) 1 µl  each 0.4 pmol/µl 
Water Ad 25 µl  
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Afterwards, 10 µl microsphere beads were added to each well for 1.5 h, washed 
throughoutly with PBS and analyzed by flow cytometry. 
 
2.2.12. Chemotaxis assay 
For the chemotaxis assay, 1x105 cells were transferred into culture plate inserts in an 24-
well-plate in N2-medium and incubated for 1 h at 37°C, 5 % CO2. 
Concentrations ranging from 0-20 ng/ml CX3CL1 were added into the well. After 3-4 h, 
ESdM migrated to the back side of the membrane were counted. 
 
2.2.13. Co-culture of ESdM and glioma cells 
For phagocytosis experiments, 1x106 GL261 or SMA560 cells were stained with 2 µl 
PKH26 in 198 µl Solution C for 5 min at 37°C. 1x105 cells per well of GFP-ESdM or 
knockdown cells were co-seeded with SMA560 or GL261 in N2 in chamber slides and 
cultivated for 24 hours. Monocultures of SMA560 and GL261 were used as controls. 
Slides were fixed with 4 % PFA for 15 min and covered with Moviol. For each well, 5 
randomly chosen areas were analyzed using a confocal laser scanning microscope. 
Number of total cells and of cells with internalized PKH26+ particles was assessed.  
For proliferation assay, 1x105 ESdM and GFP-SMA or GFP-GL261 were co-seeded into 
6-well dishes. For 5 consecutive days, cell number was counted and GFP+ cells were 
assessed using a fluorescence microscope.  
 
2.2.14. Annexin V staining  
Annexin V staining was performed after co-culture of ESdM with GFP-SMA560 or GFP-
GL261 in chamber slides. As a positive control, glioma cells were treated with 100 
nmol/ml okadaic acid for 24 hours. Cells were washed once with PBS and incubated with 
3 µl biotinylated Annexin V in 200 µl annexin binding buffer for 15 min. After washing 
with PBS, cells were incubated with Streptavidin-Cy3 and analyzed via fluorescence 
microscopy. 
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2.2.15. Induction of experimental autoimmune encephalomyelitis 
To prepare the reagent for immunization, 4 mg/ml MOG were diluted to 2 mg/ml in PBS. 
This mixture was then brought into emulsion with the same volume of complete Freuds 
Adjuvant (10 mg/ml M. tuberculosis in incomplete Freuds Adjuvant) using two syringes 
and a stopcock. The emulsion was incubated overnight at 4°C. 
Female C57BL/6J mice six weeks of age were used for the EAE experiments. 100 µl of 
activated MOG-emulsion were injected at each inguinal lymph node region at both sides 
of the anaesthetised animal. 100 µl of Pertussis toxin (5 ng/µl) were injected 
intraperitoneally at day of induction and 48 h later. 
 
2.2.16. Monitoring of experimental autoimmune encephalomyelitis afflicted animals 
After immunization, animal weight and clinical score were controlled on a daily basis. 
Clinical score was determined according to the following chart: 
 
Clinical score Symptoms 
0 no clinical symptoms 
1 limp tail 
2 complete limp tail and weakness of hindlimbs 
3 paraparesis of at least one hind limb 
4 complete hind limbs paraparesis and weakness of forelimbs 
5 moribund state or tetraplegia 
 
At the peak of the disease (clinical score of 3, around day 19 post immunization), mice 
were injected with PBS, GFP-transduced ESdM or NT3-GFP-transduced cells. For cell 
treatment, 4 million cells in 100 µl PBS were administered intravenously. Mice 
displaying a clinical score of at least four for a minimum of three days were euthanized 
and were not taken into account for analysis. 
 
2.2.17. Perfusion of animals 
Before perfusion, mice were anesthetized with Ketamin/Xylazin and checked for pain 
reflexes. Mice were transcardially perfused with 20 ml PBS followed by 20 ml 4% PFA. 
Spinal cords and brains were dissected and stored in 4% PFA. Neurohistopathology was 
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carried out by the working group of Prof. Dr. Marco Prinz in Freiburg as described 
previously (Prinz et al., 2006). 
 
2.2.18. Preparation of cryoslices  
For analysis of tissue, cryoslices were prepared. Organs obtained by perfusion of the 
animals were kept in PFA for 48 h and another 48 h in 30% sucrose solution. Before 
slicing, tissue was embedded in Tissue Tek and frozen. The frozen tissue was cut into 10 
to 20 µm thick slices on super frost slides with a cryostat and stored at -20°C. 
 
2.2.19. Immunohistochemistry of cryoslices  
Cryoslices were fixed in 4% PFA immediately after thawing. They were washed with 
TRIS-buffer and blocked with 10% BSA for 10 min. After washing with TRIS, they were 
incubated with the first antibody in tris(hydroxymethyl)aminomethane (TRIS) overnight. 
The slices were stained with fluorescent secondary antibody for 2 h and with DAPI for 5 
min. Slides were covered with Moviol. 
Assessment of immune cell infiltrates was performed by the working group of Prof. 
Marco Prinz in Freiburg as described previously (Prinz et al. 2006). 
 
2.2.20. Statistics 
Statistical analysis was performed using Graph Pad Prism 5 Software. For two groups, 
students t-test was used, for more groups, analysis of variance (ANOVA) followed by 
Bonferroni test was used. Data are presented as mean +/- SEM of at least three 
independent experiments. 
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3. Results 
 
3.1. Generation of embryonic stem cell lines 
 
In the first step, ESC lines were generated out of blastocysts obtained from C57BL/6 
mice. After extracting the blastocysts out of the uterus horns at day 3.5, they were seeded 
to a MEF cell layer. After 3 days, the blastocysts hatched and inner cell mass (ICM) 
expanded during the next days. First trypzination was performed at day 8, the next day 
ESC colonies formed and primary ESC lines were established (Fig.3.1).  
 
 
Fig. 3.1: Isolated blastocysts were seeded to a MEF cell layer (Day 1). After a few days, the trophoblast 
spred out (Day 3), and ICM expanded (Day 7). Primary ESC colonies formed after first trypzination 
 (Day 9). Scale bar 50 µm. 
 
For confirmation of ESC properties, the generated ESC lines were stained with antibodies 
direct against the stem cell markers Sox2, Oct4 and stage-specific embryonic antigen 1 
(SSEA1). Furthermore, ESCs were stained against alkaline phosphatase (AP). The 
generated ESC lines were positive for all tested markers, therefore were considered to be 
bona fide ESCs (Fig. 3.2).  
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Fig.3.2: Immunocytochemistry of the generated ESC lines using antibodies against stem cell markers Oct4, 
Sox2 and SSEA1. ESC colonies were costained with DAPI and stained positive for the markers. Colonies 
were also positive for AP. Scale bar 100 µm. 
 
 
3.2. Characterization of embryonic stem cell derived microglia 
 
3.2.1. Differentiation of mouse embryonic stem cells into ESdM 
By modification of a protocol for neuronal differentiation (Lee et al., 2000) an efficient 
protocol for microglia precursor cell line differentiation from murine ESCs was 
established (Napoli et al., 2009; Beutner et al., 2010). 
C57BL/6 ESCs were cultured in LIF containing medium on a MEF layer, where they 
formed typical cellular colonies (Fig. 3.3-A). After dissociation of the ESCs, EB 
formation was induced with withdrawal of LIF on non-coated petri dishes (Fig. 3.3-B). 
EBs can be recognized as round cell aggregates which are non-adherent. EBs were plated 
after 4 days and expanded in ITSFn medium (Fig. 3.3-C). The EBs attached and cells 
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started to grow out of the plated EBs. In this adherent culture, a high number of nestin 
positive cells was found (Fig.3.4-A) and expanded in presence of bFGF and laminin. 
After 7 days, growth factors were withdrawn and cells differentiated into neuronal 
precursor cells forming a neuronal network. 
 
 
Fig. 3.3: Brightfield pictures throughout the differentiation protocol. A) ESCs on MEF layer. B) EB 
formation. C) Mixed neuronal culture. D) Microglial precursor culture. E) ESdM in culture. Scale bar 200 
µm (A), 100 µm (B-E). Figure derived from Beutner et al., 2010. 
 
In this stage, β-tubulin-III positive cells were found (Fig. 3.4-B) as well as microglia-
shaped cells which could be stained for Iba1 (Fig. 3.4-B). Furthermore, cells positive for 
miroglia marker CD45 and the astrocyte marker glial fibrillar acidic protein (GFAP) were 
found in this mixed culture, but staining showed no colocalization of these markers (Fig. 
3.4-C). Microglia-shaped cells appeared as shiny round cells and started to proliferate in 
clusters (Fig.3.3-D), outgrowing other cells after three weeks post growth factor-
withdrawal. After the last step, the differentiation protocol resulted in a pure ESdM 
culture (Fig. 3.3-E) which could be stained for Iba1 and CD68 (Fig. 3.4-D). 
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Fig. 3.4: Immunocytochemistry throughout the differentiation protocol. A) Neural precursor cells at the 
third step (day 13) of the protocol. Cells were positive for nestin and nuclei were labeled with DAPI. B) 
Cells in a mixed neural culture, stained against Iba1 for microglia-like cells and β-tubulin-III for neuronal 
cells. C) Double immunostaining of astrocyte marker GFAP and microglia marker CD45 at step 3 of the 
protocol. No co-localization was visible. D) ESdM immunostained against Iba1 were also positive for 
CD68. Scale bar 20 µm (A-C), 50 µm (D). Figure derived from Beutner et al., 2010. 
 
3.2.2. Surface molecule expression of ESdM 
To define the properties of the obtained ESdM, different experiments were carried out. 
As a variety of antibodies against microglial surface markers can be purchased, the ESdM 
were analyzed via flow cytometry to confirm the microglial identity with a variety of 
different antibodies. 
The result of the flow cytometry is summarized in figure 3.5. ESdM showed a high 
expression level of the microglial surface molecules CD11b, CD11c, CD29, CD45, 
CD49, CD68, CD80, CD86 and CD115. Furthermore, expression of Trem2, F4/80, 
MHCII and CX3CR1 could be shown. Interestingly, ESdM did not express Ly6G and 
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chemokine (C-C motif) receptor 2 (CCR2). Stem cell markers like CD34, CD133 and 
cKit were undetectable or only weakly expressed. Lack of these stem cell population 
markers indicates that the ESdM are fully committed to differentiation. 
 
 
 
 
Fig. 3.5: Flow cytometry analysis of ESdM surface markers. Microglial surface markers CD11b, CD11c, 
CD29, CD45, CD49, CD68, CD80, CD86, CD115, Trem2, F4/80, MHCII and CX3CR1 were expressed. 
ESdM did not express Ly6G and CCR2. Stem cell markers such as CD34, CD133 and cKit were barely or 
not expressed. Figure modified from Beutner et al., 2010. 
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3.2.3. Relative cytokine gene transcription of ESdM 
One of the most typical features of microglia is the production of pro- or anti-
inflammatory cytokines and reactive oxygen species (ROS) upon pathological conditions. 
Therefore, gene transcript levels of nitric oxide synthase (NOS) 2, TNF-α and TGF-β of 
ESdM after stimulation for 24 hours with 500 ng/ml LPS or 500 U/ml IFN-γ were 
analyzed via qRT-PCR (Fig. 3.6-A). Upon treatment with IFN-γ, gene transcripts of 
NOS2 showed a high increase (1000-fold),  p< 0.005; whereas TNF-α transcripts were 
increased 20-fold, p<0.01. Treatment with LPS led to a similar, though weaker increase 
of NOS2 and TNF-α gene transcripts. TGF-β transcripts were almost unaffected by both 
treatments.  
 
3.2.4. Migration towards fractalkine 
Microglia are known to have chemotactical migration properties. Thus, a migration assay 
using fractalkine CX3CL1 was performed (see Fig. 3.6-B). The relative migration of 
ESdM in comparison to non-directed migration increased in a dose-dependent manner up 
to 20 ng/ml, where migration extended to almost 200% of basal migrationl level 
(p<0.005). As a control, 20 ng/ml CX3CL1 were added to both the upper and lower 
chamber to analyze to which extent the ESdM show undirected migration. This treatment 
did not lead to an increase in migration. 
 
3.2.5. Phagocytosis assay 
Another important functional aspect of primary microglia is the capacity of phagocytosis 
upon activation. This aspect of microglia function can be mimicked by an in vitro 
phagocytosis assay. The outcome of the phagocytosis assay is shown in figure 3.6-C. 
Upon stimuli with LPS, the percentage of ESdM showing uptake of two or more 
microsphere beads was increased from 20.9% for untreated cells to 31.4% for LPS 
treated cells. 
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Fig. 3.6: Functional analysis of ESdM. A) Relative cytokine gene transcription of ESdM upon treatment 
with IFN-γ (500 U/ml) or LPS (500 ng/ml) for 24 hours. Treatment increased transcription of NOS2 and 
TNF-α, transcription of TGF-β was almost unaffected. Data is presented as mean +SEM, ANOVA 
***p<0.005, **p<0.01. B) Migration assay of ESdM towards CX3CL1. ESdM migrated in a dose-
dependent manner towards the CX3CL1. Data is presented as mean +SEM, ANOVA: ***p< 0.005; 
**p<0.01. C) Phagocytosis assay, number of beads taken up was determined by fluorescence intensity. 
Phagocytic inactive cells are not shown in the histogram. Upon stimulus with 500 ng/ml LPS the uptake of 
microspheres by ESdM increased. Figure published in Beutner et al., 2010. 
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3.2.6. RNA microarray of ESdM and primary microglia 
To confirm the identity of the ESdM as microglia cells, a RNA microarray was 
performed to compare the gene expression of primary microglia to ESdM by the lab of 
Andrea Staratscheck-Jox at the LIMES institute, Bonn, Germany. 
Out of 44 000 analyzed genes, about 20 000 genes were found to be expressed in ESdM 
and primary microglia. Of the genes expressed, over 19 000 were coexpressed by ESdM 
and primary microglia in a similar dimensions. Only about 1 000 of the expressed genes 
were not found in both samples and were therefore expressed selectively. 
Table 3.1 lists a selection of genes assigned to different cell types. Microglial genes like 
Trem2, CD206 or MHCI were expressed in a high amount in both ESdM and primary 
microglia. However, genes assigned to astrocytes like GFAP or neurons like Nestin are 
only weakly expressed. The same holds true for ESC genes like Sox2 and Myc. These 
results indicate that ESdM are fully commited to differentiation and share a similar 
genetic profile with primary microglia. 
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Tab. 3.1: Selection of genes expressed by ESdM and primary microglia (pMG). Microglial genes like 
Trem2 or CD206 are expressed by both ESdM and primary microglia in a comparable high amount. Genes 
assigned to astrocytes, neurons or ESCs were barely expressed. 
 
Gene       Entrez Gene #  ESdM  pMG _______            
Microglia genes 
Mrc1 or CD206 mannose receptor  17533   4107,7  2041,6 
H2-Q2 (MHCI) histocompatibility 2 15013   1657,8  1821,8 
Cd63 antigen    12512   3462,6  4978,9 
Tnf, tumor necrosis factor   21926   298,9  1054,2 
Trem2, triggering receptor expressed 83433   5232,8  10981,9 
on myeloid cells 2 
Siglec1, sialic acid binding  20612   149,3  1134,0 
Ig-like lectin 1 
Astrocyte genes 
Gfap, glial fibrillary acidic protein  14580   80,0  78,6 
Bmp2, bone morphogenetic protein 2 12156   83,9  86,6 
Olig2, oligodendrocyte TF 2  50913   79,3  75,5 
Neuron genes 
Nefm, neurofilament   18040   85,0  82,4 
Tubb3, tubulin, beta 3   22152   90,1  87,1 
Nes, nestin    18008   79,0  191,6 
ESC genes 
Nanogpd,similar to Nanog homeobox 634428   78,6  73,5 
Sox2,SRY-box containing gene 2  20674   74,8  77,6 
Myc, myelocytomatosis oncogene  17869   66,1  72,4 
 
 
 
3.2.7. Subdifferentiation of ESdM into neurotoxic and neuroprotective subtypes 
For subdifferentiation of ESdM, cells were treated with 100 U/ml IFN-γ and 5 ng/ml LPS  
or with 20 ng/ml IL-4 for 24 hours, respectively. After stimulation, RNA was isolated 
and qRT-PCR was performed for several marker genes assigned to M1 or M2 microglia 
subtypes (see Fig. 3.7). 
ESdM treated with IFN-γ and LPS showed a significant upregulation of genes assigned to 
the M1 microglia subtype like iNOS, CXCL10 and TNF-α.  
  Results 
 
 55
On the other hand, treatment of ESdM with IL-4 led to an increase in genes assigned to 
the M2 subtype, among these are arginase I (Arg), IL-10, found in inflammatory zone 1 
(Fizz1) and YM1 (Mantovani et al., 2004). Except for Fizz1, the upregulation was 
specific for IL-4 treatment.  
 
 
Fig. 3.7: Results of qRT-PCR for genes assigned to M1 or M2 subtype after treatment of ESdM with      
100 U/ml IFN-γ and 5 ng/ml LPS or 20 ng/ml IL-4. Treatment with IFN-γ and LPS led to an upregulation 
of genes from the M1 subtype, namely iNOS, CXCL10 and TNF-α. Upon stimulus with IL-4, ESdM 
showed higher expression of anti-inflammatory genes assigned to the M2 subtype such as Arg, IL-10, 
Fizz1, and YM1. Data are presented as mean + SEM and analyzed using one way anova followed by 
Bonferroni; ***p<0,005, **p<0,01. 
 
For immunocytochemistry, cells were treated for 24 hours with IFN-γ and LPS or for 48 
hours with IL-4. The subdifferentiated cells were immunolabelled with antibodies 
directed against surface markers of M1 and M2 microglia subtypes (Kigerl et al., 2009); 
(see Fig. 3.8). The treatment with IFN-γ and LPS led to a more intense staining for M1 
subtype markers CD86, iNOS and CD16/32. On the other hand, treatment with IL-4 
resulted in a slight increase of fluorescence for Arg and CD206, markers assigned to the 
neuroprotective subtype of microglia. 
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Fig. 3.8: Immunocytochemistry for antibodies directed against surface markers of M1 and M2 subtype. 
IFN-γ + LPS-treatment resulted in an increase in expression of CD86, iNOS and CD16/32. Treatment with 
IL-4 led to an increase in expression of Arginase I and CD206. Scale bar 100 µm. Diploma student Celine 
Ruegsegger contributed to this figure. 
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3.3. Therapy of experimental autoimmune encephalomyelitis by NT3-
GFP-ESdM 
 
3.3.1. Lentiviral transduction of ESdM 
For experiments performed to determine the effect of ESdM on EAE afflicted mice, 
ESdM were transduced with GFP or GFP and NT3 using a lentiviral vector system. NT3-
GFP-ESdM cells stained positive for NT3 (Fig. 3.9-A). The constitutive expression of 
NT3 was also confirmed by qRT-PCR (Fig 3.9-B). 
 
Fig.3.9: A) Immunocytochemistry of NT3-GFP-ESdM in comparison to control GFP-ESdM using an 
antibody against NT3. Transduced cells showed a strong signal, whereas the control cells did not stain for 
NT3. Scale bar: 50µm. B) Relative gene transcription of NT3 analyzed via qRT-PCR. 
 
3.3.2. Effects of NT3-GFP-ESdM supernatant on neurons in vitro 
In order to analyze the beneficial effect of NT3 expressed by ESdM on neurons, primary 
neuronal cultures were treated with either water, GFP-ESdM supernatant, NT3-GFP-
ESdM supernatant or recombinant NT3 (10ng/ml) for  48 hours (see Fig. 3.10). In 
comparison to supernatant of GFP-ESdM, supernatant of NT3-GFP-ESdMs strongly 
promoted neurite outgrowth demonstrated by an increased immunoreactivity for GAP43 
(Fig.3.10-A). Furthermore, neurons cultured in presence of recombinant NT3 or NT3-
GFP-ESdM supernatant appeared to be more viable and showed more axons than those 
treated with GFP-ESdM or water. Quantification of GAP43+ neurites showed that in 
water control 3.2% +/- 2.2% of neurites stained positive, treatment with GFP-ESdM 
resulted in 19.1% +/- 5.0% of GAP43+ neurites. Supernatant of NT3-GFP-ESdM 
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resulted in 82.2% +/- 3.6%, the positive control of recombinant NT3 led to 90.5% +/- 
6.5% of GAP43+ neurites (Fig. 3.10-B). 
 
 
Fig. 3.10: A) Neurons cultured in medium supplemented with water, GFP-ESdM supernatant, NT3-GFP-
ESdM supernatant or recombinant NT3 stained for β-III-Tubulin and GAP43. NT3-GFP-ESdM supernatant 
resulted in an increase in GAP43 staining, indicating neurite growth. Scale bar 100 µm. B) Quantification 
of GAP43+ neurites. Statistical analysis via ANOVA followed by Bonferroni, *p<0.05; ***p<0.0001.   
 
  Results 
 
 59
3.3.3. Migration and engraftment of ESdM into inflammatory spinal cord lesions  
EAE was induced by injection of activated MOG-emulsion to both inguinal lymph node 
regions to female C57BL/6J mice. After about 12 days, the mice displayed the first 
symptoms of disease, starting with a limp tail. For all experiments, only animals showing 
symptoms at day 14 and a clinical score of 3 at day 19 were included. 
At a clinical score of 3 (20 days post induction), 4 million GFP-ESdM were injected 
intravenously to investigate the fate of the ESdM. After 24 hours, a small number of GFP 
positive cells could be found in the lumbal part of the spinal cord. The GFP positive cells 
were located in close vicinity to the inflammatory lesions of the spinal cord. The number 
of GFP-ESdM increased over time, indicating a stable engraftment of ESdM in the tissue 
(Fig. 3.11-B). Furthermore, the GFP-signal of the ESdM colocalized with Iba1-staining, 
showing that the ESdM engrafted as microglial cells in the nervous tissue. (Fig. 3.11-A). 
 
 
Fig. 3.11: A) Longitudinal cryosections of spinal cord from EAE afflicted mouse, 10 days post injection of  
GFP-ESdM, stained for Iba1 and DAPI, scale bar 50 µm. B) Quantification of GFP+ cells at several time 
points after cell injection, data are presented as mean + SEM and analyzed via one way anova followed by 
Bonferroni; *p<0,05. Vera Lenerz and Ruslan Masgutov contributed to this figure. 
 
3.3.4. Clinical improvement of EAE after transplantation of NT3-GFP-ESdM 
At a clinical score of 3 (day 20), EAE-afflicted mice were treated with an intravenous 
injection of 4x106 GFP-ESdM, NT3-GFP-ESdM or 100 µl PBS. Injection with both 
ESdM-types had a significant beneficial effect on the clinical symptoms. The mice were 
found to recover significantly and showed less severe onset of the disease (Fig. 3.12). 
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Whereas the GFP-transduced ESdM displayed a mild therapeutical effect on EAE-
afflicted mice, administration of NT3-GFP-ESdM had an even stronger effect. 
Treatment with NT3-GFP-ESdM additionally impeded the tendency to relapse after first 
recovery. This effect could not be seen upon treatment with GFP-ESdM or PBS.  
 
 
Fig. 3.12: Clinical score of EAE mice until day 40 post induction. Mice were treated with either PBS, GFP-
ESdM or NT3-GFP-ESdM, administered at day 20 intravenously. Data are presented as mean +/-SEM, 
PBS n=25; GFP-ESdM n=27; NT3-GFP n=28, data was analyzed via one-way anova followed by 
Bonferroni: (**p<0,01 for PBS versus NT3-GFP-ESdM from day 25 to day 30; ***p<0,005 for PBS versus 
NT3-GFP-ESdM from day 30 to day 40). 
 
3.3.5. Axonal injury and demyelination after transplantation of NT3-GFP-ESdM 
40 days post induction of EAE, the mice were perfused and brains and spinal cord were 
collected for further analysis. The following histopathological stainings and 
quantifications were performed at the Institute of Neuropathology in Freiburg, Germany 
by Angela Dann in the working group of Prof. Marco Prinz. 
To reveal the impact of the treatment with NT3-GFP-ESdM on the grade of 
demyelination, cryoslices of the spinal cords were stained with Luxol Fast Blue (LFB); 
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(Fig. 3.13-A). LFB stains the myelin sheaths in nervous tissue blueish, whereas neurons 
are stained violet. Treatment with NT3-GFP-ESdM led to a reduction of the 
demyelinated area from 44.6% +/- 3.5 % (PBS treated control) to 31.8% +/- 2.8 % 
(Fig.3.13-C). 
Axonal damage was obtained via staining against amyeloid precursor protein (APP) 
(Fig.3.13-B). Axonal damage was decreased in mice treated with NT3-GFP-ESdM  
(25.1% +/- 2.1 %) in comparison to PBS treated control mice (38.8% +/- 3.2 %) (Fig. 
3.13-D). 
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Fig. 3.13: A) Cryoslices of spinal cords derived from EAE afflicted mice 40 days post induction stained 
with LFB for myelin. Mice were treated with PBS, GFP-ESdM or NT3-GFP-ESdM. LFB staining shows 
that PBS mice suffered more demyelination in comparison to ESdM-treated mice. Scale bar upper row 
500µm; scale bar lower row 200 µm B) Cryoslices of spinal cords derived from EAE afflicted mice 40 days 
post induction stained for APP, scale bar 200 µm.C) Quantification of the demyelinated area in spinal cord 
sections, * p < 0.5.Data are presented as mean + SEM. D) Quantification of axonal damage,  
* p < 0.5, data are presented as mean + SEM. Data was obtained in collaboration with Prof. Marco Prinz. 
 
3.3.6. Number of invading T cells and macrophages into spinal cord tissue  
For further comparison of the disease severity in the three different treatments, the 
number of inflammatory infiltrates into the nervous tissue was obtained (Fig. 3.14).  
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Thus, cryoslices of spinal cords were stained with antibodies against macrophage antigen 
(MAC) 3 for macrophages or CD3, a marker for T cells (Fig.3.14-A, B). For the 
macrophages, the mice treated with ESdM transduced with GFP or GFP and NT3 show a 
slightly lower infiltration into the spinal cord. However, differences in macrophage 
infiltrates are not significant inbetween the three groups. For the T cell infiltrates, the 
same holds true. No differences could be found regarding the number of T cell infiltrates 
into the spinal cord within the different treatments (Fig. 3.14-C, D). 
 
 
 
Fig. 3.14: A) Staining of spinal cord cryoslices of EAE afflicted mice 40 days post induction treated with 
PBS, GFP-ESdM or NT3-GFP-ESdM against macrophages (MAC-3) and B) T cells (CD3). Scale bar 
200µm. C) Quantification of macrophages and D) T cells infiltrates in the spinal cord. The differences are 
not significant. Data are presented as mean + SEM. Data obtained in collaboration with Prof. Marco Prinz. 
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3.3.7. Anti-inflammatory and growth promoting effect of NT3-GFP-ESdM 
To analyze if the NT3-GFP-ESdM had additional beneficial effects by mediating the 
cytokine milieu in the spinal cord, qRT-PCR was performed with RNA derived from 
spinal cords four days post injection of PBS, GFP-ESdM or NT3-GFP-ESdM (Fig. 3.15). 
The cytokine profile obtained by this method revealed that the treatment with NT3-GFP-
ESdM resulted in a shift of the cytokine profile towards an anti-inflammatory milieu. A 
downregulation of the pro-inflammatory cytokines iNOS, TNF-α, IL-1β and TGF-β 
could be detected upon treatment with NT3-GFP-ESdM. A similar, but weaker effect was 
found upon treatment with GFP-ESdM in comparison to PBS treated mice. However, 
TGF-β has not been downregulated after treatment with GFP-ESdM. For the anti-
inflammatory cytokine IL-10, an upregulation was detected upon treatment with NT3-
GFP-ESdM, as well as for NT3 itself. 
 
 
Fig.3.15: Quantitative realtime PCR for cytokine profile 4 days post injection of PBS, GFP-ESdM or NT3-
GFP-ESdMs. Injection of NT3-GFP-ESdM resulted in an anti-inflammatory milieu. Data are presented as 
mean + SEM, ***p<0.005, **p<0.01. 
 
The beneficial impact observed in the in vitro experiment for neurite growth effects of 
NT3 (see chapter 3.3.2) could be seen in vitro as well, as NT3-GFP-ESdM had a positive 
effect on neurons. Cryosections of the spinal cord could be stained for GAP43, a marker 
for neurite outgrowth, indicating a neuronal regenerative effect (Fig. 3.16-A). 
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Quantification of GAP43+ cells in the spinal cord showed a significant increase after 4 
days post treatment with NT3-GFP-ESdM in comparison to PBS or GFP-ESdM (Fig. 
3.16-B). 
 
 
Fig. 3.16: A) Staining of spinal cord cryoslices 4 days post injection of NT3-GFP-ESdM. Slices were 
immunolabeled with GAP43. Scale bar 50µm.  B) Quantification of GAP43+ cells at different time points 
post injection, treatment with NT3-GFP-ESdM led to an increase of GAP43+ cells. Data are presented as 
mean + SEM of three independent experiments. Statistical analysis via ANOVA followed by Bonferroni, 
*p<0.05; **p<0.01; ***p<0.0001. Vera Lenerz contributed to this data. 
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3.4. Phagocytosis of glioma cells through ESdM 
 
3.4.1. Co-culture of ESdM with SMA560 and GL261 glioma cells 
To study the in vitro effects of ESdM on glioma cells, co-culture experiments were 
performed following analysis of glioma cell number and phagocytosis. Lentiviral 
transduced GFP-SMA560 or GFP-GL261 glioma cells were co-cultured with ESdM and 
the glioma cell number was determined every day for 5 days (Fig. 3.17). A pure glioma 
culture was used as a control. In the pure culture, both glioma cell lines displayed an 
exponential growth, whereas the GFP-GL261 expanded slower than the GFP-SMA560 
line. In co-culture with the ESdM, the growth rate of glioma cells was significantly 
decreased in both experiments. After 5 days, the mono-culture of GFP-SMA560 
expanded to 528.8x104 +/-67.8x104 cells, in presence of ESdM they reached 247.7x104 +/- 
87.0x104 cells. The GFP-GL261 cell line alone expanded to 149.0x104 +/- 23.1x104 cells, 
the ESdM reduced that cell number to 64.0x104 +/- 4.6x104 cells at day 5. 
 
 
Fig. 3.17: A) Quantification of SMA560 glioma cells in co-culture with ESdM in comparison to a pure 
SMA560 culture. In co-culture, SMA560 showed a lower expansion of cell number. Data is presented as 
mean +/- SEM. Statistical analysis via students t-test, ***p<0.0001. B) Quantification of GL261 glioma 
cells in presence or absence of ESdM. Co-culture with ESdM led to lower GL261 cell numbers. Data is 
presented as mean +/- SEM. Statistical analysis via students t-test, ***p<0.0001. 
 
To confirm that the reduction of glioma cells in the cell culture was not due to an increase 
in apoptosis, staining with Annexin V was performed. GFP+ glioma cells were cultured 
  Results 
 
 67
alone or in presence of ESdM. After 24 hours, the cultures were stained with Annexin V 
and the number of positive GFP+ cells was determined. In GFP-SMA560 culture, 4.0% 
+/- 0.7% of cells stained positive for Annexin V, whereas in the co-culture with ESdM 
5.8% +/- 3.0 % were apoptotic. For GL261, the mono-culture showed 5.4% +/- 3.9%, the 
co-culture showed 4.2% +/- 2.0% of apoptotic cells. As a positive control, GFP-SMA560 
and GFP-GL261 were treated with 100ng/ml okadaic acid for 24 hours. Treatment 
resulted in 86.2% +/- 5.8% apoptotic GFP-SMA560 cells and in 86.3% +/- 9.0% 
apoptotic GFP-GL261 cells (Fig.3.18). 
 
 
Fig. 3.18: Co-cultures of ESdM and GFP-SMA560 or GFP-GL261 and mono-cultures of the glioma lines 
were stained with Annexin V after 24 hours. As a positive control, glioma cultures were treated with 100 
nmol/ml okadaic acid (OA) for 24 hours. Analysis via ANOVA and Bonferroni test, no significant 
differences were found inbetween the glioma cultures and the co-cultures with ESdM. Data is presented as 
mean + SEM.  
 
3.4.2. Phagocytosis of SMA560 and GL261 glioma cells by ESdM  
As the reduction of glioma cells was not due to an increase of apoptosis, a phagocytosis 
experiment was performed. Thus, ESdM were lentivirally transduced with GFP and 
cultured with PKH26 fluorescent dye labeled SMA560 or GL261 glioma cells. The 
uptake of glioma cells by ESdM was visualized using confocal microscopy (Fig. 3.19-A). 
In both cases, GFP-ESdM showed an uptake of fluorescent particles, which indicates 
phagocytosis of glioma cells through GFP-ESdM. In the co-culture with SMA560 cells, 
46.6% +/- 11.1% of the total ESdM cell number showed uptake of PKH26+ particles. For 
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the co-culture with GL261 glioma cells, an uptake from 60.8% +/- 7.8% was seen (Fig. 
3.19-B). 
 
 
Fig. 3.19: A) Confocal imaging of co-cultures of GFP-ESdM with GL261 or SMA560. In both cases, GFP-
ESdM showed uptake of PKH26+ particles. Scale bar: 50 µm.  
B) Quantification of GFP-ESdM which showed uptake of PKH26+ particles in co-culture with SMA560 or 
GL261 glioma cells, data is presented as mean + SEM.  
 
 
Z-Stack-Imaging revealed that the GFP-ESdM have indeed taken up the glioma cells, as 
the red signal of PKH26+ particles was located inside the cells (Fig. 3.20) 
 
 
Fig. 3.20: Z-stack confocal imaging of GFP-ESdM with internalized PKH26+ particles. Particles are 
located inside the GFP-ESdM. Scale bar: 20 µm 
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3.4.3. Effect of polarized ESdM on glioma proliferation and phagocytosis 
To further evaluate the effect of ESdM on glioma cells in co-culture, ESdM were treated 
for 24 hours with IFN-γ (100 U/ml) + LPS (5 ng/ml) for M1 polarization or with IL-4 (20 
ng/ml) for M2 polarization. The subpolarized ESdM were used for the co-culture with 
GFP-SMA560 or GFP-GL261 to find out if the polarization of ESdM affects glioma 
growth rate or phagocytosis capability of ESdM. The proliferation assay revealed that the 
subpolarization into M2 subtype had no significant effects on the growth behaviour of 
glioma cells in co-culture. GFP-SMA560 grew to 590.9 x104 +/- 84.2 x104 cells in a single 
culture after 5 days, in co-culture with ESdM that number was reduced to 209.1 x104 +/- 
7.9 x104 cells. M2 polarized cells showed a similar result with 217.8 x104 +/- 23.7 x104 
GFP-SMA560 cells. Subpolarization of ESdM into M1 subtype decreased the glioma cell 
number a bit more to 166.1 x104 +/- 18.6 x104 cells (Fig.3.21-A). Although this result did 
not reach significance, a difference between GFP-SMA560 cell numbers in control ESdM 
and M1 co-culture could be found at day 3. Similar effects of subpolarization were found 
in the GFP-GL261 set-up. The single culture reached 253.0 x104 +/- 28.7 x104 cells 
culture with control ESdM reached 161.7 x104 +/- 24.9x104 cells. Treament of ESdM for 
M2 subtype was almost equal to control ESdM (162.9 x104 +/- 14.9 x104). Subpolarization 
into M1 type resulted in an expansion of GFP-GL261 cells to 145.5 x104 +/- 23.2 x104 
cells. Again, significance was obtained at day 3 in comparison to non-treated ESdM 
(Fig.3.21-B). 
Quantification of phagocytosis showed that M1 treatement resulted in an increase of 
phagocytosis in co-culture with SMA560. Control ESdM reached 37.0% +/- 6.1%, M1 
ESdM reached 64.5% +/- 13.9%. Treatment for M2 polarization did not have an effect in 
comparison to the control and resulted in 38.4% +/- 7.5%. 
In co-culture with GL261 glioma cells, 62.3% +/- 5.0% of control ESdM showed uptake 
of PKH26+ particles. M1 treatment increased that value to 79.8% +/- 7.3%. M2 treatment 
resulted in a slightly lower uptake, 55.2% +/- 1.8% of M2 ESdM showed uptake of red 
particles (Fig.3.21-C). 
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Fig. 3.21: Effects of ESdM on glioma proliferation and phagocytosis after subpolarization into M1 and M2 
subtype. A) Quantification of SMA560 cell number in co-culture with ESdM, M1 and M2 polarized ESdM. 
B) Quantification of the co-culture of ESdM, M1 or M2 ESdM with GL261 cells. Data is presented as 
mean +/- SEM. Statistical analysis via ANOVA followed by Bonferroni, + p<0.05; ++/**p<0.01; 
***p<0.0001. + indicates the significance in comparison to the wildtype ESdM, * in comparison to the 
glioma mono-culture. C) Quantification of uptake of PKH26+ particles by non-treated ESdM, M1 treated 
or M2 treated ESdM after 24 hours of co-culture with SMA560 or GL261 glioma cells. Data is presented as 
mean + SEM. Statistical analysis via ANOVA followed by Bonferroni, *p<0.05. 
 
As polarization of ESdM into M1 subtype led to an increase in phagocytosis of glioma 
cells, analysis was performed in regard to phagocytosis-associated receptors. FACS 
analysis confirmed that M1 polarized ESdM showed a higher expression of SiglecH and 
Trem2 (Fig. 3.22) in comparison to non-stimulated cells. 
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Fig. 3.22: FACS analysis for Trem2 and SiglecH expression of untreated ESdM control and ESdM treated 
with IFN-γ (100 U/ml) + LPS (5 ng/ml) for M1 subpolarization. Stimulation resulted in a higher expression 
of Trem2 and SiglecH.  
 
3.4.4. Effects of DAP12 in glioma proliferation and phagocytosis through ESdM 
The protein DNAX activation protein of 12 kDa (DAP12) is known to play an important 
role in phagocytosis, as it is associated with phagocytic receptors such as SiglecH and 
Trem2. Therefore, the effects of DAP12 overexpression and DAP12 dominant negative 
mutation with lacking immunoreceptor tyrosine-based activation motif (ITAM) domain 
were analyzed in regard to glioma cell proliferation and phagocytosis of glioma cells 
through GFP-ESdM. 
The proliferation assay revealed that the cell number in both cell-cultures is decreased 
through ESdM. The mono-culture of SMA560 expanded to 553.1x104 +/-60.0 x104 cells, 
in presence of ESdM to 322.9 x104 +/- 26.9 x104 cells. The overexpression of DAP12 
further decreased the SMA560 cell number to 246.9 x104 +/- 18.2 x104 cells, whereas the 
DAP12 lacking ITAM ESdM only had little but significant effect on the glioma cell 
number of 409.4 x104 +/- 15.5 x104 cells. The GL261 cell line alone expanded to 99.3 x104 
+/- 6.4 x104 cells, the ESdM reduced cell number to 61.1 x104 +/- 2.5 x104 cells. In co-
culture with DAP12 lacking ITAM ESdM GL261 culture almost reached cell numbers 
like in the mono-culture with 91.7 x104 +/- 4.5 x104 cells, the difference is not significant. 
The overexpression of DAP12 in ESdM led to an even stronger decrease of GL261 cell 
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number. GL261 cells in presence of DAP12 overexpressing cells expanded to 47.4 x104 
+/- 15.2 x104 cells (Fig.3.23-A, B). 
The phagocytosis experiments resulted in a matching result, as the ESdM lacking DAP12 
ITAM domain only showed low uptake levels (17.5% +/- 9.3% for SMA560 and 22.7% 
+/- 7.7% for GL261 co-culture) of PKH26+ particles. The overexpressing cells showed a 
higher uptake level (76.1% +/- 12.4% for SMA560 and 77.3% +/- 6.2% for GL261 co-
culture) in comparison to the co-culture with control ESdM (53.9% +/- 9.1% for 
SMA560 and 58.7% +/- 9.6% for GL261 co-culture) (Fig. 3.23-C). 
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Fig. 3.23: Effects of DAP12 on glioma proliferation and phagocytosis through ESdM. A) Quantification of  
SMA560 cell number in co-culture with ESdM, DAP12 overexpressing ESdM (DAP12 OE) and DAP12 
lacking ITAM ESdM (DAP12 wo ITAM). Lacking ITAM resulted in a smaller effect of ESdM on glioma 
cell number in comparison to the control ESdM. Overexpression of DAP12 increased the reducing effect of 
ESdM on SMA560 cells. B) Quantification of the co-culture of ESdM, DAP12 overexpressing ESdM and 
DAP12 lacking ITAM ESdM with GL261 cells. Overexpression of DAP12 decreased the GL261 cell 
number, whereas lacking ITAM domain in the DAP12 resulted in a weaker effect of ESdM. Data is 
presented as mean +/- SEM. Statistical analysis via ANOVA followed by Bonferroni, */+ p<0.05; 
**p<0.01; ***p<0.0001. + indicates the significance in comparison to the wildtype ESdM, * in comparison 
to the mono-culture. C) Quantification of uptake of PKH26+ particles by ESdM, DAP12 overexpressing 
ESdM and DAP12 lacking ITAM ESdM after co-culture with SMA560  and GL261 glioma cells. Data is 
presented as mean + SEM. Statistical analysis via ANOVA followed by Bonferroni, **p<0.01. 
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3.4.5. Effects of SiglecH on glioma proliferation and phagocytosis through ESdM 
To evaluate the role of SiglecH in uptake of glioma cells through ESdM and the effect of 
glioma cell growth rate, SiglecH was knocked down using a lentiviral vector approach. 
Confirmation of the knock-down was performed via qRT-PCR. Treatment of ESdM with 
the knock-down plasmid aimed at SiglecH led to a 10-fold decrease of gene transcript in 
comparison to ESdM treated with a control scramble RNAi plasmid (Fig.3.24). 
 
Fig. 3.24: Lentiviral knock-down of SiglecH (SigH KD) resulted in a 10-fold lower gene transcript level 
than in corresponding control ESdM. Data is presented as mean +SEM, statistical analysis via students  
t-test, **p<0.005   
 
The SiglecH knock-down ESdM polarized into M1 subtype were used for phagocytosis 
assay and in the co-culture system with glioma cells to determine if the knock-down 
altered the behaviour of ESdM or glioma cells. 
In regard to cell expansion of the SMA560 or GL261, the SiglecH knock-down cells had 
a smaller reducing effect than the control. SMA560 cells alone reached 504.4 x104 +/- 
65.8 x104 cells after 5 days, in presence of ESdM that number decreased to 172.7 x104 +/- 
30.4 x104 cells. Knock-down of SiglecH lowered the effect of ESdM, SMA560 expanded 
to 357.0 x104 +/- 11.8 x104 cells (Fig.3.25-A). 
In GL261 culture, cells grew to a cell number of 171.3 x104 +/- 34.3 x104 cells, ESdM 
decreased that cell number to 66.9 x104 +/- 4.3 x104 cells. The knock-down of SiglecH in 
ESdM resulted in a milder effect of ESdM, GL261 expanded to 142.9 x104 +/- 28.5 x104 
cells (Fig.3.25-B).  
The phagocytosis assay showed that knock-down of SiglecH altered the uptake of glioma 
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cells through ESdM. In co-culture with SMA560, control ESdM showed an uptake of 
39.2% +/- 11.3%, whereas the SiglecH knock-down only showed an uptake rate of 18.2% 
+/- 5.4%. In co-culture with GL261 cells, 63.0% +/- 8.0% of ESdM showed uptake of 
PKH26+ particles. The knock-down of SiglecH reduced the uptake to 19.2% +/- 8.0% 
(Fig. 3.25-C). 
 
 
Fig. 3.25: Effects of SiglecH knock-down on glioma proliferation and phagocytosis through ESdM.    
A) Quantification of  SMA560 cell number in co-culture with control ESdM and SiglecH knock-down 
ESdM (SigH KD). B) Quantification of the co-culture of ESdM and SiglecH knock-down ESdM with 
GL261 cells. Data  of A and B is presented as mean +/- SEM. Statistical analysis via ANOVA followed by 
Bonferroni, */+ p<0.05; **p<0.01; + indicates the significance in comparison to the wildtype ESdM, * in 
comparison to the mono-culture. C) Quantification of uptake of PKH26+ particles by ESdM and SiglecH 
knock-down ESdM in co-culture with SMA560 or GL261 glioma cells. Data is presented as mean + SEM. 
Statistical analysis via students t-test, *p<0.05, ***p<0.0001. 
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3.4.6. Role of Trem2 in glioma proliferation and phagocytosis through ESdM 
As a second phagocytic receptor in microglia-glioma-interaction, Trem2 is a suitable 
candidate. Thus, Trem2 was knocked down in ESdM using the lentiviral system. FACS 
analysis showed that the knock-down was successful, as lower levels of Trem2 were 
found after treatment with knock-down plasmid targeted for Trem2 (Fig.3.26). 
 
 
 
Fig. 3.26: Validation of Trem2 knockdown via FACS. Control ESdM showed an intense signal for Trem2 
expression, whereas the signal of the ESdM lentivirally transducted with Trem2 shRNA expressed lower 
levels of Trem2. 
 
The Trem2 knock-down cells were used for proliferation assay and phagocytosis 
experiments to analyze the effect of the knock-down.  
During the proliferation assay, SMA560 cells expanded to 504.3 x104 +/- 50.5 x104 cells 
in 5 days. Co-culture with ESdM reduced glioma cell number to 184.3 x104 +/- 25.7 x104, 
knock-down of Trem2 in ESdM in co-culture resulted in 299.6 x104 +/- 25.5 x104 
SMA560 glioma cells (Fig.3.27-A). GL261 glioma cells reached 182.7 x104 +/- 31.2 x104 
cells, in presence of ESdM they reached 71.0 x104 +/- 6.7 x104. In co-culture with Trem2 
knock-down ESdM, GL261 cells expanded to 106.0 x104 +/- 9.0 x104 cells (Fig.3.27-B).  
In regard to phagocytosis of glioma cells, Trem2 knock-down led to a decrease in 
phagocytosis capacity of ESdM in co-culture with glioma cells. Co-cultured with 
SMA560 glioma cells, control ESdM showed an uptake rate of 46.5% +/- 6.7%, knock-
down of Trem2 decreased the phagocytosis activity to 31.9% +/- 5.4%. In case of the 
GL261 glioma cells, 59.4% +/- 9.2% of control ESdM showed uptake of PKH26+ 
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particles. The knock-down of Trem2 resulted in a trend to lower uptake levels with 
46.0% +/- 4.3% (Fig.3.27-C). 
 
 
Fig. 3.27: Effects of Trem2 knock-down on glioma proliferation and phagocytosis through ESdM. 
A) Quantification of  SMA560 cell number in co-culture with control ESdM and Trem2 knock-down 
ESdM (Trem2 KD). B) Quantification of the co-culture of ESdM and Trem2 knock-down ESdM with 
GL261 cells. Data  of A and B is presented as mean +/- SEM. Statistical analysis via ANOVA followed by 
Bonferroni, + p<0.05; **p<0.01; ***p<0.005; + indicates the significance in comparison to the wildtype 
ESdM, * in comparison to the mono-culture. C) Quantification of PKH26+ particle-uptake by ESdM and 
Trem2 knock-down ESdM in co-culture with SMA560 or GL261 glioma cells. Data is presented as mean + 
SEM. Statistical analysis via students t-test, *p<0.05. 
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4. Discussion  
 
4.1. Derivation of embryonic stem cell lines  
 
The establishment of pluripotent cells from mouse embryos was firstly described in 1981 
(Evans and Kaufman, 1981) and is still considered to be a breakthrough in cell biology.  
The ICM of a blastocyst represents a pluripotent cell population which gives rise to all 
embryonic tissue including germline cells (Bradley et al., 1984). As ESCs are derived 
from that unique cell population, they share the capacity of differentiating into all cell 
types. Defined culture conditions including LIF result in ESC lines with self-renewing 
and indefinite growth capacities without senescing (Williams, 1988; Miura et al., 2004).  
Germline competent ESCs can be used for gene targeting and furthermore to generate 
genetically modified mice strains (Schoonjans et al., 2003). 
During the last years, ESCs have also been used for drug-assays and for the development 
of stem cell based therapy approaches and are therefore considered to be a powerful tool 
in disease modeling (Prelle et al., 2002). The protocols for establishing ESC lines have 
been revised and improved in the last decade and result in a high yield of lines which are 
suitable for screening experiments (Cheng et al., 2004; Bryja et al., 2006). 
Seeding of blastocysts to a MEF layer resulted in primary ESC lines, which could be kept 
in culture for several passages. All derived ESC lines were positive for Sox2, Oct4 and 
SSEA1 and stained positive for AP. 
The transcriptions factors Sox2 and Oct4 are essential in developmental processes in 
mammals through the regulation of other essential genes involved in embryonic 
development (Kiefer, 2007; Nichols et al., 1998). Their main function is to maintain self-
renewal and to keep cells from differentiation. It has been demonstrated that knock-down 
of Sox2 or Oct4 gene leads to embryonic lethality and promotes the differentiation of 
ESCs in culture (Niwa et al., 2000; Chew et al., 2005). 
SSEA-1 is another well known marker for murine pluripotent stem cells, its main 
function lies in regulation of adhesion and migration of cells during embryonic 
implantation (Kerr et al., 1992). Elevated levels of AP are typically found on the 
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membrane of ESCs and can therefore be used as a ESC marker (Kuegler et al., 2010). 
The generated ESCs could successfully be differentiated into neuronal precursors and 
finally into microglial cells. Nevertheless, to fully ensure ESC properties, lines have to be 
tested for the ability to differentiate into cells of all three germ-layers.  
The generation of ESC and the subsequent differentiation into ESdM bears a high 
potential for studying the effects of genetic diseases especially in regard to microglial 
function.  
 
 
 
4.2. Characterization of embryonic stem cell derived microglia 
 
4.2.1. Generation of ESdM 
Microglia functions are often studied on primary microglia cells, which can be isolated 
and enriched from mixed glial cell cultures derived from the brains of postnatal mice. As 
an alternative, primary microglia can be directly isolated from adult brain tissue by 
density gradients and flow cytometry sorting (Havenith et al., 1998; Ford et al., 1995). 
Cell yield obtained by these protocols is rather low and not sufficient for biochemistry of 
systematic screening methods. Therefore, oncogenically transformed microglia cell lines 
such as BV2 have often been used (Blasi et al., 1990; Bocchini et al., 1992). But, 
oncogenic transformation might lead to a limited reflection of microglial properties, 
likely making microglial cell lines a poor substitute for primary microglia.  
In contrary to primary microglia, murine ESCs provide unlimited self-renewal capacity 
and can differentiate into cell types of all three germ layers. Recently, a protocol for 
differentiation of microglia-like cells from murine ESC was described (Tsuchiya et al., 
2005). 
To overcome the problems mentioned above, a protocol for differentiation of mouse 
ESCs into microglia precursor cells was established (Napoli et al., 2009; Beutner et al., 
2010). The developed protocol is based on a protocol for neuronal differentiation (Lee et 
al., 2000) and was initiated by the finding that microglia-like cells can be found next to 
neural cells differentiated from EBs (Tsuchiya et al., 2005). 
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During development, primitive yolk sac macrophages start to populate the 
neuroepithelium as microglia precursor cells around embryonic day 7.5 (Ginhoux et al., 
2010).  Microglia precursor cells start to proliferate locally until date of birth to finally 
differentiate into the resident pool of adult microglia (Alliot et al., 1999). ESdM were 
derived via a protocol which mimics brain development from EBs. EBs show both 
neurogenesis and yolk-sac like hematopoieses (Keller et al., 1993). Therefore, ESdM are 
likely differentiated through a yolk-sac like primitive macrophage precursor cell and 
reflect in vivo microglia development. 
ESCs were differentiated into ESdM and characterized. ESdM provide the possibilities to 
study the microglia functions without oncogenic transformation and an insufficient cell 
number. Additionally, the protocol could be applied to a broad range of ESC derived 
from transgenic mice, resulting in genetically modified ESdM. The differentiation 
resulted in high cell amounts of proliferative ESdM, which could be kept in culture up to 
25 passages without losing their properties. 
 
 
4.2.2. Phenotype and genotype of ESdM 
In the protocol applied to the ESCs, ESdM are generated via EB formation which are 
plated. In the plated EBs, a variety of cell types appeared, e.g. contracting heart muscle 
cells.  In the neural differentiation step, immunostaining revealed a mixed cell population 
positive for neural precursors, glial and microglial cell markers. 
The Iba1+/CD45+ cells could be further cultured in defined medium to a homogenous 
population of ESdM. ESdM could be stained for the classical microglia markers Iba1 and 
CD68, with no negative cells present. Hence, the differentiation protocol resulted in a 
pure ESdM population. 
Several markers assigned to the microglial phenotype were found.  Microglia are 
described as CD68+, CD45 low, CD11b+, CD11c high, MHC class II+, IBa1+ and 
F4/80+, CD18+ cells (Guillemin and Brew, 2004; Ford et al., 1995).  
To determine the phenotype of ESdM in regard to surface marker expression, FACS 
analysis was performed. The ESdM showed expression of CD11b, CD11c, CD29 (β1 
integrin), CD45, CD49, CD68, CD80, CD86 (B7.2) and CD115. Additionally, expression 
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of Trem2, F4/80, MHCII and CX3CR1 could be shown. All these markers are membrane 
proteins assigned to monocytes, microglia and macrophages (Austyn and Gordon, 1981; 
Ford et al., 1995; Napoli et al., 2009, Ulvestad et al., 1994; Jung et al., 2000). The 
surface expression of these markers is comparable to primary microglia. The presence of 
β1 integrin and the co-stimulatory molecule CD86 indicate that the ESdM are capable of 
immunoregulatory functions.  
ESdM showed no expression of Ly6G and CCR2, which is a hallmark of regulatory 
monocytes which home to non-inflamed tissue (Geissmann et al. 2003). This pool of 
resident monocytes patrols blood vessel walls and also replaces tissue macrophages. In 
comparison, Ly6G+/ CCR2+ monocytes are referred to as inflammatory monocytes, 
which are present in the circulating blood and migrate to inflamed tissues (Ransohoff, 
2011).  
ESdM were virtually negative for cKit and CD34, which are markers for stem cells. The 
lack of these stem cell population markers indicates that the cells are fully commited to 
differentiation. Thus, ESdM display microglial precursor cells identity.  
 
In addition to the analysis of the phenotype, a RNA microarray was carried out to further 
validate the ESdM identity. The array confirmed the previous findings and showed a 
comparable gene expression of primary microglia and ESdM. Of the 44 000 genes 
analyzed, about 20 000 genes were found to be expressed in both primary microglia and 
ESdM. Of those expressed genes, more than 19 000 genes were coexpressed in both cell 
types, whereas less than 1 000 were expressed selectively. Furthermore, the genes 
coexpressed were mostly found in comparable amounts in ESdM and primary microglia. 
Of the genes coexpressed, genes assigned to microglia such as CD206, CD63, TREM2 or 
MHCI were found in high amounts. However, genes assigned to other cell types like 
GFAP and Olig2 (astrocyte genes), β-III-tubulin and nestin (neuronal genes) or Nanog 
and Sox2 (ESC genes) were only weakly expressed. Thus, ESdM express a similar 
genetic profile like primary microglia. Additionally, the microarray data mirror the full 
commitment of ESdM to differentiation and their microglial identity. 
 
 
 
  Discussion 
 82
4.2.3. Functionality of ESdM 
To further reveal the properties of the ESdM, a variety of functional assays was 
performed. One of the typical properties of microglia is the production of pro-
inflammatory cytokines and ROS upon pro-inflammatory stimuli (Hanisch, 2002). To 
mimic the in vivo situation in the cell culture, the inflammatory stimuli LPS and IFN-γ 
were used to induce cytokine production by ESdM. Data were obtained via qRT-PCR 
with primers against NOS2, TNF-α and TGF-β. Treatment of ESdM with IFN-γ resulted 
in an increase of NOS2 by a factor of 1000 and a 20-fold increase of TNF-α transcripts. 
Treatment with LPS increased the expression of NOS2 and TNF-α, but to a lower extent 
than the treatment with IFN- γ. The transcripts of TGF-β remained almost unaffected by 
both treatments. This might be due to the fact that ESdM were not exposed to intrinsic 
and extrinsic factors present in the brain. 
NOS2 is a member of a family of enzymes that contributes to neuronal transmission and 
the immune system. NOS2 synthesizes nitric oxide from the terminal nitrogen atom of L-
arginine (Ignarro et al., 2001). The nitric oxide can react with superoxide leading to 
peroxynitrite formation and cell toxicity. Thus, NOS2 is believed to play a role in host 
immunity, anti-microbial and anti-tumor responses via the oxidative burst of 
macrophages (Chinje et al.,1997). 
TNF-α is cytokine involved in the acute phase reaction or systemic inflammation. The 
major function of TNF-α is the regulation of immune cells, but it is known to be involved 
in inflammation, apoptosis and inhibition of tumorigenesis (Old et al., 1985; Gaur et al., 
2003). It is known that macrophages and microglia release large amounts of TNF-α in 
response to LPS or other bacterial products (Gosselin and Rivest, 2007). The inducibility 
of NOS2 and TNF-α indicates that IFN- γ and LPS are immunostimulatory substances for 
ESdM in vitro and that ESdM react to inflammatory stimuli comparable to primary 
microglia.  
The also analyzed TGF-β is one of the cytokines of the TGF-family. TGF-β has 
multifunctional properties and is, among others, involved in cell proliferation and 
differentiation. Furthermore, it has a direct anti-inflammatory impact on Th1 cells 
signaling (Massagué et al., 1992). Due to its anti-inflammatory properties, TGF-β is also 
involved in tumor progression and immune suppression (Michiel et al., 1992). 
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Another feature of microglial cells is the capability of migration. To study the migratory 
potential of ESdM, a migration assay using CX3CL1 was performed. CX3CL1 is 
constitutively expressed by neurons in a soluble and a membrane-bound form, which 
both promotes chemotaxis (Re and Przedborski, 2006). It was previously shown that 
microglia express the corresponding receptor CX3CR1 in a GFP-CX3CR1 transgenic 
mouse (Jung et al., 2000). Napoli et al. showed in 2009 that ESdM express CX3CR1 to a 
similar extent as primary microglia (Napoli et al., 2009). Therefore, one could expect that 
ESdM migrate towards CX3CL1 in a microglia-like fashion. Using a transwell migration 
system, the migration of ESdM towards different concentrations of CX3CL1 was 
analyzed. The outcome clearly showed that ESdM are capable of migration in a dose-
dependant manner. Migration rate increased up to a concentration of 20 ng/ml CX3CL1 
and almost doubled in comparison to non-directed migration. Thus, ESdM respond to the 
CX3CL1 by migration along a concentration gradient towards the source of the 
chemokine. 
 
Activated microglia are known to perform phagocytosis, which is a highly coordinated 
process and mainly regulated by environmental signals (Napoli and Neumann, 2008). 
One of the standard assays to determine the phagocytosis capacity of cells is the uptake 
of fluorescent microsphere beads (Steinkamp et al., 1982). Therefore, ESdM were 
incubated with fluorescent microsphere beads and number of positive cells was 
determined via flow cytometry. Unfortunately, it is not possible to distinguish between 
cells that have ingested beads and cells with beads attaching at the cell surface. Thus, 
only cells with a higher fluorescence signal than from one bead were taken into account. 
The assay revealed that over 20% of the ESdM were phagocytically active. In order to 
activate the ESdM, they were treated with LPS, which led to an increase in microsphere 
bead uptake. To further improve this method, a threshold for unspecific fluorescence of 
beads on the cell surface could be obtained by using cytochalasin-D, which blocks 
phagocytosis (Robinson, 1978).    
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4.2.4. Subdifferentiation of ESdM  
It is known for several years that cells from the monocyte-macrophage lineage are 
heterogenous in regard to the response to microenvironmental signals and can be 
distinguished into several alternative polarized activation modes (Gordon et al., 2003; 
Mosser et al., 2003). The classical activation of macrophages via microbial molecules of 
pro-inflammatory cytokines results in a phenotype called M1, which produces pro-
inflammatory cytokines and NO. The alternative activation leads to a phenotype called 
M2, which is considered an anti-inflammatory subtype (Mantovani et al., 2004). The M1 
and M2 subtype represent the most extreme forms of the polarization continuum, as 
macrophages can undergo a highly differentiated modulation of properties in response to 
their environment. 
So far, little is known about the capacity of microglia to undergo a similar 
subpolarization. However, some evidence for microglia subdifferentiation arouse during 
the last years. Butovsky and colleagues showed in 2006 that microglia stimulated with 
IL-4 are able to support neuronal survival, oligodendrogensis and neurogenesis 
(Butovsky et al., 2006). Most recently, some pioneer work was accomplished regarding 
the differentiation spectrum of M1 and M2 microglia (Michelucci et al., 2009). The 
publication nicely showed that upon stimuli with IFN-γ cells expressed the inflammatory 
cytokines IL-6 and TNF-α, whereas stimulation with IL-10 resulted in expression of anti-
inflammatory cytokines. 
To evaluate whether the generated ESdM would react in a similar fashion, they were 
treated with IFN-γ and LPS to trigger the M1 (neurotoxic) or with IL-4 for the M2 
(neuroprotective) subdifferentiation. Treatment with IFN- γ and LPS resulted in an 
upregulation of genes assigned to the M1 subtype, namely iNOS, CXCL10 and TNF-α. 
Immunocytochemistry revealed that ESdM treated for neurotoxic subdifferentiation 
expressed CD86, iNOS and CD16/32, which goes along with the findings in 
macrophages (Mantovani et al., 2004). Treatment of ESdM with IL-4 on the other hand 
resulted in gene expression of anti-inflammatory molecules such as arginase, FizzI, IL-10 
and YM1. Staining against arginase and CD206 showed that cells treated with IL-4 
expressed slightly more of these M2 markers than ESdM treated with  IFN-γ and LPS. 
These findings indicate that the ESdM are capable to subdifferentiate into different 
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subtypes, but additional experiments have to be performed to further validate the 
outcome of the experiments. If later experiments will proof the successful 
subdifferentiation of ESdM, it would be of prosper interest to apply the subdifferentiated 
cells into mouse models of neurodegenerative diseases to evaluate the neurotoxic versus 
the neuroprotective properties of the ESdM subtypes. 
 
 
4.3. Therapy of experimental autoimmune encephalomyelitis by NT3-
GFP-ESdM 
 
 
MS is the most prevalent cause of disability caused by neurological impairment in young 
adults. The hallmarks of MS are immunce cell infiltration, demyelination and axonal 
damage (Hemmer et al., 2002). As the CNS fails to remyelinate the axons in the lesion 
sites, disease course results in irreversible functional losses of patients (Ferguson et al., 
1997).  
Recent studies have shown that transplantation of neural precursor cells in EAE afflicted 
mice attenuated the inflammatory processes and clinical severity of disease (Einstein et 
al., 2003; Pluchino et al., 2005). The role of microglia implemented in MS disease makes 
them a potential target for therapeutical approaches. In MS, they not only attack the 
myelin sheeth of neurons, they also secrete inflammatory cytokines. Thus, altering 
microglia properties in favor of neuro-protective functions could resolve inflammation in 
MS lesions and lead to beneficial effects in regard to disease course. As NT3 is one of the 
most potent neurotrophins and has been shown to enhance neuronal regeneration, it was 
used to genetically modiefy ESdM used for therapeutic experiments in EAE afflicted 
mice.  
 
4.3.1. Beneficial effects of NT3-GFP-ESdM supernatant on neurons in vitro 
ESdM were lentivirally transduced with vectors expressing GFP or GFP and NT3 under 
the constitutively active PGK-promotor to evaluate the effects of NT3 in in vitro 
experiments.  
NT3 was shown to exert a neuroregenerative effect in axonal injury (Guo et al., 2006) 
and to play a pivotal role in cortical reorganization after spinal cord injury (Ramu et al., 
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2007). Furthermore, NT3 was demonstrated to enhance axonal plasticity in injured spinal 
cords of rats (Zhou et al., 2003). It is closely linked to survival and maintenance of a 
variety of neural populations and stimulates axonal outgrowth and neurogenesis (Chen et 
al., 1996; Memberge et al., 1995).  
 
Thus, one would expect a positive effect of the supernatant from NT3-GFP-ESdM on 
neurons, as the supernatant likely contains a sufficient amount of NT3 to trigger neuronal 
regeneration. To validate this hypothesis, primary cultures were exposed to either water, 
GFP-ESdM supernatant, NT3-GFP-ESdM-supernatant or recombinant mouse NT3. After 
72 hours, the neuronal cultures were stained for GAP43, which is highly expressed in 
neuronal growth cones. Therefore, GAP43 can be used as a marker for neuronal growth 
and plasticity (Benowitz et al., 1997). Staining for GAP43 revealed a growth promoting 
effect of the NT3-GFP-ESdM supernatant on the neuronal culture.  
Neurons cultured with medium supplemented with either supernatant of NT3-GFP-ESdM 
or 10 ng/ml recombinant NT3 showed a strong staining intensity for GAP43. 
Furthermore, neurons cultured under these two conditions appeared to be more viable and 
more axons were found. Taking together, these findings indicate that the secretion of 
NT3 by NT3-GFP-ESdM is sufficient to trigger GAP43 expression and therefore 
promote neuronal outgrowth in primary neuronal cultures. 
 
4.3.2. Effect of NT3-GFP-ESdM on experimental autoimmune encephalomyelitis 
          afflicted mice in vivo 
To reveal the effect of transduced ESdM in vivo, EAE-afflicted mice were treated with 
PBS, GFP-ESdM or NT3-GFP-ESdM. EAE was induced by injection of activated MOG-
emulsion into both inguinal lymph node regions of female C57BL/6J mice. About 12 
days post induction, the first clinical symptoms could be seen. The clinical score of the 
mice rose to a clinical score of 3 at day 19. 
To determine if the ESdM migrate to the EAE lesion sites in the spinal cord, a migration 
analysis was performed. Thus, spinal cord samples were collected and analyzed at 
different time points after intravenous GFP-ESdM cell injection. Already 24 hours post 
injection, GFP-positive cells could be found in the lumbal part of the spinal cord in close 
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vicinity to the inflamed regions. As the number of GFP positive cells increased over time, 
one could assume that the ESdM stably engraft in the spinal cord tissue. It is most likely 
that the migration of ESdM is due to the attraction to the inflammatory sites via 
chemokines. One of the candidates to orchestrate this migration is CX3CL1, as it is 
reported to be highly expressed in EAE (Sunnemark et al., 2005). Though, the question 
remains if the grade of inflammation plays a role in the migration process of ESdM to the 
lesion sites, as ESdM did not home to the CNS in healthy mice. Apparantly, an 
inflammatory stimulus derived from the spinal cord lesions is necessary for the homing 
process. The co-localization of GFP with the microglial marker Iba1 additionally 
indicates the microglia fate of the ESdM upon engraftment in the spinal cord tissue. 
Taken together, these findings show that ESdM are a suitable tool to locally deliver 
trophic substances to the lesion sites as physiological vehicles. 
 
Until now, several studies aiming at various therapeutical approaches for EAE as a model 
for MS have been carried out. Previous to our work, it has been shown that human neural 
precursors derived from ESCs have a therapeutic effect on EAE-afflicted mice 
(Aharonowiz et al., 2008). Human neural precursors had a similar beneficial effect on the 
clinical course of EAE like ESdM, but had to be transplanted into the lateral brain 
ventricles due to lacking migratory capacities. 
In addition to NT3, a variety of other neurotrophic factors have been shown to abate the 
disease course of EAE. For example, the administration of NGF as well as ciliary 
neurotrophic factor (CNTF) was shown to reduce inflammation in EAE afflicted rats 
(Flügel et al., 2001; Linker et al., 2002).  
It was postulated by Caggiula et al. that neurotrophins are promising candidates for MS 
due to the link between neurotrophin levels and complete remission of MS in the post-
relapse phase (Caggiula et al., 2005). Neurotrophins have been shown to be expressed 
endogeneously by T cells and other immune cells in human MS lesion sites (Hohlfeld et 
al., 2006). In EAE, T cells and NK cells infiltrating the CNS produced NT3 and BDNF 
and potentially promoted neuronal protection during disease course (Hammarberg et al., 
2000). Furthermore, injection of NT3, but not of BDNF was shown to enhance 
regenerative sprouting in the corticospinal tract and enhanced neuronal repair (Schnell et 
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al., 1994). Lentiviral introduction of a NT3 gradient in the spinal cord lesion was also 
shown to increase the number of ascending sensory axons extending into the lesion sites 
(Taylor et al., 2006). Thus, NT3 was chosen as a representative candidate for gene 
transfer in EAE. 
 
Still, neuroregeneration remains a major challenge and is, among other issues, addressed 
in the here presented experiments. 
To analyze the clinical course of the EAE after injection of 4 million GFP-ESdM or NT3-
GFP-ESdM in comparison to PBS, the clinical score of the mice was measured on a daily 
basis. After administration of the cells or PBS on the clinical peak (score 3) of the 
disease, a beneficial effect could be observed upon cell treatment. Treatment with GFP-
ESdM resulted in a mild improvement of clinical scores in comparison to the control 
group. However, the group treated with NT3-GFP-ESdM showed a highly significant 
decrease of clinical scores compared to both the PBS and the GFP-ESdM treated mice. 
This positive effect of the NT3-GFP-ESdM is most likely due to the local administration 
of NT3 to the spinal cord lesions, which promotes neurite outgrowth and helps to 
attenuate the inflammatory properties of the lesion sites. The following discussion will 
reveal further insights into the mechanisms underlying the beneficial effect of NT3-GFP-
ESdM on EAE afflicted mice. 
 
4.3.3. Evaluation of axonal injury and demyelination 
One of the major hallmarks of MS and the murine model EAE is the demyelination of 
neurons followed subsequently by axonal injury and degeneration. Thus, the grade of 
demyelination and axonal injury in the spinal cord was obtained 40 days post induction of 
EAE after treatment with PBS, GFP-ESdM or NT3-GFP-ESdM, respectively.  
Staining for myelin with Luxol Fast Blue showed smaller demyelinated areas in NT3-
GFP-ESdM treated animals in comparison to the control group. This decresased LFB 
staining represents either demyelination itself or loss of myelin due to axonal destruction. 
These data indicate that the treatment with NT3-GFP-ESdM scotches the inflammatory 
mechanisms underlying the demyelination process and/or leads to a higher remyelination 
rate in the inflammatory lesions. 
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In case of axonal damage, APP accumulates in the axons and becomes detectable through 
immunological staining. Axonal damage was significantly decreased in mice treated with 
NT3-GFP-ESdM.  
It is known that microglia and macrophage cell activation contributes to MS and EAE 
pathology by antigen presentation to T cells and secretion of pro-inflammatory cytokines 
(Benveniste, 1997). The antigen presentation of microglia is based on the expression of 
molecules such as MHC class II, CD83 or CD40, which are essential for interaction of 
microglia with T and B cells (Aravalli et al., 2007; Raivich and Banati, 2004). 
Furthermore, the expression of TLR is crucial for generation of neuroimmune responses 
(Jack et al., 2007; Lee and Lee, 2002).  
Rasmussen and colleagues demonstrated the persistent activation of microglia in the 
chronic phase of relapsing-remitting EAE, which leads to loss of neuronal synapses 
(Rasmussen et al., 2007). More directly, activated microglia are not only involved in 
antigen presentation and inflammatory signaling, but contribute to the degradation of 
myelin through phagocytosis (Bauer et al., 1994).  
On the other hand, microglia were shown to also have a beneficial role in MS and EAE 
pathology. To give an example, microglia can secrete anti-inflammatory cytokines like 
IL-10 and TGF-β depending on the milieu in the CNS (Napoli and Neumann, 2009). This 
could explain the positive effect of GFP-ESdM on EAE afflicted mice, as secretion of 
these cytokines would decrease the inflammatory response and therefore weaken disease 
severity. Furthermore, microglia are capable of secretion of neurotrophic factors such as 
insulin-like growth factor-1 (IGF-1), BDNF or NT3, which might contribute to 
promoting neurogenesis (Napoli and Neumann, 2009). The stronger therapeutical effect 
of NT3-GFP-ESdM compared to GFP-ESdM nicely fits into these findings. 
 
4.3.4. Immune cell infiltrates  
As mentioned in chapter 4.2.1., microglia as well as macrophages play a pivotal role in 
MS and EAE pathology. Thus, the severity of EAE can be determined via the number of 
invading macrophages into the spinal cord. Staining for MAC-3, a macrophage marker, 
revealed that the number of macrophages does not differ significantly in the case of PBS 
and NT3-GFP-ESdM treated animals.  
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Another cell type which can be used to evaluate EAE disease is the T cell. In the EAE 
model used in this study, autoreactive myelin antigen-specific CD4+ T cells are activated 
and expanded within the peripheral lymphoid tissue (Wekerle et al., 1994). 
Approximately 10 days post immunization with MOG, activated T cells start to cross the 
BBB in massive amounts, whereas non-activated T cells are unable to infiltrate into the 
CNS (Flügel et al., 2001). The invasion of activated T cells subsequently leads to further 
recruitment and activation of T cells and production of effector cytokines. These 
cytokines attract immune cells like granulocytes, microglia and macrophages which 
further mediate inflammation and demyelination (Dijkstra et al., 1992). Thus, EAE 
pathogenesis can be considered to be mostly T cell mediated as they orchestrate the 
autoimmune demyelinating inflammation in the CNS.  
The analysis of T cell invasion in the EAE mice treated with either PBS, GFP-ESdM or 
NT3-GFP-ESdM revealed that the T cell number does not differ significantly in these 
groups. This finding indicates that the severity of disease was the same in all cases, 
therefore the therapeutic effect was due to the cell treatment. 
 
 
4.3.5. Cytokine milieu and neural regeneration 
In order to further analyze the underlying mechanisms of the beneficial effect of NT3-
GFP-ESdM on EAE disease course, analysis of cytokine expression levels of the lumbal 
spinal cord tissue was performed 4 days after treatment via qRT-PCR. The results clearly 
showed a significant down-regulation of the pro-inflammatory cytokines iNOS, TNF-α, 
and IL-1β. Additionally, expression of anti-inflammatory cytokines NT3, TGF-β and IL-
10 were found to be increased upon treatment with NT3-GFP-ESdM. Administration of 
GFP-ESdM resulted in a similar trend which mirrors the outcome of the analysis of the 
clinical score. Thus, GFP-ESdM and especially NT3-GFP-ESdM are able to promote an 
anti-inflammatory milieu in EAE lesions. 
This finding might be the main cause for the therapeutic effect of the injected cells, as an 
interruption of the inflammatory signaling would abandon the mechanisms resulting in 
demyelination and neuronal injury. The cytokine micromilieu established by microglia 
was furthermore shown to determine the course of inflammatory processes in EAE, thus 
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is one of the important features to be addressed in therapeutical approaches (Carson, 
2002; Heppner et al., 2005). 
 iNOS is involved in the production of NO, a soluble cytotoxic mediator of macrophages 
which induces a reversible conduction block in demyelinated axons and axonal 
degeneration (Redford et al., 1997). TNF-α as well as IL-1β are the most prominent 
cytokines which can be detected at the lesion sites of the CNS. They are released by 
activated microglia and inhibit neural outgrowth (Neuman et al., 2002). Furthermore, 
they are known to induce neuronal cell death (Merrill et al., 1992). 
IL-10 and TGF-β both down-regulate the immune response and are closely linked to 
benign course of MS symptoms (Link, 1998; Navikas et al., 1995). TGF-β is additionally 
known to be involved in T cell response inhibition (Navikas et al., 1996). The observed 
upregulation of NT3 is clearly due to the presence of the NT3-GFP-ESdM, its beneficial 
effects have already been discussed.  
Staining for the neurite outgrowth marker GAP43 revealed that in presence of NT3-GFP-
ESdM, neurons regenerate in the EAE lesions in the spinal cord. This regenerative effect 
could be seen as the most important outcome of the study, as neural regeneration still 
remains a major problem in MS research. 
Taken together, the anti-inflammatory milieu created by the administration of GFP-NT3-
ESdM might be the key to the therapeutic effect and might play a crucial role for further 
therapeutical investigations. 
 
4.3.6. NT3-GFP-ESdM as a tool for multiple sclerosis therapy 
The results presented here revealed a promising possibility for NT3-GFP-ESdM as 
therapeutical tool for EAE. Using ESdM yields a couple of advantages in comparison to 
bone marrow derived myeloid precursor cells in respect to homing and engraftment 
properties.  
ESdM are derived from a protocol mimicking the in vivo development of microglia 
including a yolk sac intermediate stage. They are able to cross the BBB after intravenous 
application in response to a lesion-associated trigger in the adult CNS without any 
physical or pharmacological manipulation of the organism. Furthermore, ESdM could be 
detected in the CNS up to 21 days post injection in the EAE spinal cord lesions, whereas 
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bone marrow derived cells disappear after four days (Takahashi et al., 2007). Another 
advantage is the phenotype of the ESdM, which shows similarities to regulatory 
monocytes and M2 polarized macrophages (Rae et al., 2007; Geissmann et al., 2003). 
ESdM without genetic modification did not have any effect on the clinical score of EAE 
but also stably engrafted into the lesion sites.  
Another advantage of ESdM is their availability in high numbers and pure cultures. 
Therefore, ESdM appear to be a safe and well suited tool for CNS gene therapy 
(Neumann, 2006). 
 
Some problems and concerns still remain to be overcome to further validate this potential 
in regard to MS therapy. 
Evaluating the results, one has to keep in mind that EAE cannot be equaled to MS, 
although EAE is used as a common model for MS. To give an example, the mechanisms 
underlying MS are still unclear (Degenhardt et al., 2009), therefore it is difficult to 
compare MS to EAE. Nevertheless, EAE and MS share some disease features like the 
inflammatory lesions, immune cell infiltration, demyelination and axonal regeneration 
(Kornek et al., 2000). It is therefore likely that at least part of the here discussed results 
found in murine EAE can be transferred to human MS. 
The usage of NT3 as neurotrophic factor in this study might arise some further 
objections. It was reported that the systemic administration of high doses of NT3 in 
animal models evokes pronounced pain and gastrointestinal symptoms (Thoenen et al., 
2002). Something similar could be observed in humans in a clinical trial after 
intracerebroventricular infusion of another neurotrophic factor, NGF, which resulted in a 
constant pain sensation (Eriksdotter Jönhagen et al., 1998). Anyway, it is not known if 
the delivery of NT3 used in this study does result in similar complications. If so, one 
would need alternatives to neurotrophic factors in general. It has been discussed 
previously that high dosages of neurotrophins might result in severe side effects such as 
epileptic activity (Binder et al., 2001). In this here presented approach, these effects can 
be overcome due to the local administration of the NT3, which is effective in lower 
dosages and does not involve systemic side-effects. No visible side-effects in the mice 
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treated with NT3-GFP-ESdM could be seen, thus one would not expect major 
complications in treatment of patients with MS. 
For further perspectives, especially for clinical trials in humans, the differentiation 
protocol presented here was modiefied to differentiate human induced pluripotent stem 
(iPS) cells into microglial cells. This might clear the way for broad application fields for 
the therapeutical usage of ESdM in neurodegenerative research. ESdM appear as a 
suitable vehicle and a promising tool to be used in therapeutical approaches for MS. 
 
 
4.4. Phagocytosis of glioma cells through ESdM 
 
Due to the highly invasive growth pattern of glioma cells, glioma are barely curable by 
standard therapies such as surgical resection, radio- and chemotherapy. In most cases, 
infiltrating glioma cells remain in the healthy tissue and cause tumor reformation. The 
role of microglia in tumor progression has been broadly discussed as they are known to 
be capable of acting in favor or against the tumor. Altering microglia properties could 
therefore be used in a therapeutical approach for glioma. 
 
4.4.1. The cell lines GL261 and SMA560 
In order to evaluate the effect of ESdM on glioma cells co-culture experiments with 
GL261 and SMA560 glioma cell lines were performed.   
The GL261 glioma cell line is a commonly used mouse model for human glioblastoma. 
The original GL261 tumor was induced by intracranial injection of 3-methylcholantrene 
into C57BL/6 mice and maintained through serial transplantations of tumor pieces into 
syngeneic mice (Ausman et al., 1970). Thus, GL261 thus were derived through artificial 
induction, which might not fully portray spontaneously arising human tumors. 
Nevertheless, tumors derived from GL261 cells have similar growth characteristics and 
angiogenic properties like human glioblastoma. Mouse in vivo experiments have shown 
the invasive growth property of GL261, that is the main reason for therapy failure in 
human patients (Newcomb and Zagzag, 2009). Furthermore, GL261 cells carry point 
mutations in the K-ras and p53 gene, which are also frequently found in cells derived 
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from human glioblastoma (Szatmári et al., 2006). Thus, GL261 cells are used as a valid 
model for glioblastoma therapy. As the GL261 line is derived from C57BL/6 mice, it 
represents the syngeneic situation in the experiments, as ESdM are derived from the same 
mouse strain.  
To further test the effectiveness of ESdM, a non-syngeneic set-up was also performed. 
For this purpose, the SMA560 cell line was used. In contrast to the artificially derived 
GL261 line, SMA560 cell line is derived from a spontaneously developing astrocytic 
tumor in VM/Dk mice. This mouse strain has a high incidence of spontaneous 
astrocytoma development (Fraser et al., 1971). It has been demonstrated that the cell line 
is highly tumorigenic, retains glial differentiation features and produces high levels of 
TGF-β (Sampson et al., 1997).  
Both cell lines fulfill the requested properties of a valid animal glioma model as 
postulated by Wilson. They are of glial origin, capable of intraparenchymal growth, 
uniformly fatal in reasonable time, transplantable intracranially and subcoutaneously, 
correspond with therapeutic sensivity of human glioblastoma and can be cultured in vitro 
(Wilson, 1978). 
Thus, these cell lines were used to assess data about interaction of ESdM with glioma 
cells to evaluate the therapeutical potential of ESdM. Both glioma cell lines were 
influenced at a similar level by the ESdM, thus the genetic background of the cell appears 
to have no effect on ESdM interaction with glioma cells. 
 
4.4.2. The effects of ESdM on glioma cells 
In proliferation assays it was shown that the presence of ESdM reduced the cell number 
of GL261 and SMA560, whereas control mono-cultures of glioma cells showed 
exponential growth rates. Therefore, the reduction of growth was not due to the N2 
medium lacking FCS in which the experiments were performed. Glioma cells showed a 
similar growth behaviour in glioma medium containing FCS. It is also quite unlikely that 
the reduced cell number is caused by lack of space or nutrition, as glioma cells are able to 
grow in hypoxic and ischemic condition and grow in three-dimensional cell agglomerates 
upon space restriction (Gorin et al., 2004). Nevertheless, one has to keep in mind that 
lacking FCS or splitting procedure before co-seeding might influence glioma cell 
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susceptibility to ESdM attack. The observed effect might also be more severe in vitro 
than in vivo, as tumor supporting cells like lymphocytes or endothelial cells are absent 
(Watters et al., 2005). Interestingly, data obtained by the diploma student Julia Reinhardt 
also showed that the timing of seeding cells is of importance. Pre-seeded glioma cells 
showed less susceptibility to ESdM growth inhibition. This might be caused by the pre-
established micromilieu of the glioma cells which overrides the immune response of 
microglia cells (Wiendl et al., 2002). 
The experiment did not reveal the cause of reduced glioma numbers, which could be due 
to decreased proliferation, enhanced apoptosis or phagocytosis of glioma cells by 
microglia. To further determine this aspect, Annexin V staining was performed to assess 
number of apoptotic cells in the co-culture system. The experiment showed that apoptosis 
levels were comparable in pure glioma cultures and co-cultures with ESdM. Thus, the 
reduced cell number in the co-culture is not due to an increase in apoptosis. Mora et al. 
could show that activated microglia decreased proliferation and migration of glioma cells 
and furthermore triggered autophagy-dependent glioma cell death (Mora et al., 2009). 
The processes underlying the microglial anti-tumor properties are most likely mediated 
by chemokines produced by the ESdM. A study with primary microglia and microglia 
cell line BV-2 has previously shown that CathepsinB secretion by microglia might be 
involved in anti-tumor effects (Hwang et al., 2009). 
An analysis of the chemokine profile of the ESdM after co-culture with glioma cells 
performed by Kristian Welle revealed an upregulation of CX3CL1, CXCL9 and 
CXCL10. The soluble form of CX3CL1 is known to potently attract T cells and 
monocytes via interaction with the receptor CX3CR1 (Imai et al., 1997).  
CXCL9, also known as monokine induced by gamma interferon (MIG) is also a T cell 
chemoattractant, which is induced by IFN-γ. This chemokine interacts with the 
chemokine receptor CX3CR1 (Farber et al., 1997). The third upregulated chemokine 
CXCL10 (also known as interferon inducible protein 10, IP-10) is also secreted in 
response to IFN-γ. This chemokine plays a role in several mechanisms, including 
chemoattraction of monocytes/macrophages, T cells, NK cells and dendritic cells, 
promotion of T cell adhesion to endothelial cells, anti-tumor activity and inhibition of 
angiogenesis (Sarris et al., 1995; Angiolillo et al., 1995; Farber et al., 1997). 
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The induction of these cytokines is likely to mediate an anti-tumor milieu which 
subsequently leads to a decrease in tumor cell growth.  
 
One of the major functions of microglia and macrophages is phagocytosis of microbes, 
dead cells or debris in the CNS. Experiments could show that the ESdM indeed 
phagocytosed glioma cells as particles of PKH26+ glioma cells were found inside ESdM 
after co-culture for 24 hours with SMA560 or GL261 cells. Microglia are furthermore 
capable of triggering glioma apoptosis through production of NO and cytotoxic 
molecules (Hwang et al., 2009; Mora and Régnier-Vigouroux, 2009). In contrast, a 
mechanism which is called silent phagocytosis is taking place without inducing 
inflammatory processes (Kurosaka et al., 2003). It has been postulated by Fadeel et al. 
that apoptosis is not neccessary for phagocytosis of glioma cells, but that the cell surface 
expression of molecules engaging phagocytic cells termed “eat me signal” is sufficient 
(Fadeel et al., 2004). The equal level of apoptosis in the co-culture hints towards this 
phagocytosis mechanism, which can be referred to as “buried alive”.  
 
During the last years, evidence arose that the accumulation of microglia in glioma is due 
to a local production of various chemoattractants and growth factors by the glioma cells. 
For example, monocyte chemotactic protein 1 (MCP-1, also known as CCL2) is secreted 
by glioma cells and interacts with the microglial receptor CCR2 (Galasso et al., 2000). 
Additionally, various gliomas secrete growth factors which are known to induce 
macrophage/microglia proliferation such as CSF-1 or granulocyte-colony stimulating 
factor (G-CSF) (Alterman et al., 1994). Despite the fact that microglia are recruited in 
high numbers to the tumor site, phagocytosis of glioma cells or debris by those microglia 
was not observed (Hao et al., 2002). Furthermore, even a tumor promoting role has been 
proposed for microglia, as they might facilitate immunosuppression of the tumor 
microenvironment (Badie et al., 2001). The secretion of MMP by microglia is one 
example for a proces which can help to increase the tumor proliferation rate (Rao et al., 
2003). Umemura et al. demonstrated that tumor-infiltrating microglial cells obtain an 
immuno-suppressive phenotype and promote TGF-β production via an autocrine loop 
(Umemura et al., 2008). This immuno-suppressive role of microglia and the promoted 
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anti-inflammatory cytokine mileu play a crucial role in tumor tolerance, as both leads to 
CD4+ T cell tolerance and inactivation of cytotoxic CD8+ T cell mediated tumor targeted 
immune responses (Carpentier and Meng, 2006). It was nevertheless shown that the 
immuno-suppression of the glioma can be conquered. One attempt to overcome the 
immunosuppression was performed by Carpentier and colleagues, who demonstrated 
long-term survival of rats with glioma after single-dose administration of CpG 
oligodeoxynucleotide, an immuno-stimulatory molecule that enhances microglial 
production of IFN-α, IFN-β, IL-12 and TNF-α via stimulation of TLR9 (Carpentier et al., 
2000; Auf et al., 2001).  Furthermore, IL-12 restores anti-cancer properties of microglia 
and enhances elimination of cancerous cells (Chiu et al., 2011) and could be thus used to 
further increase anti-tumor properties of ESdM. 
Apparantly, ESdM were able to overcome the immunosuppression at least in the in vitro 
co-culture and diminished glioma cell number through phagocytosis. 
 
4.4.3. Effect of ESdM polarization 
It was demonstrated that especially the classical activated M1 subtype is known for 
killing tumor cells. On the other hand, the M2 subtype shows pro-tumoral properties by 
suppressing immune responses (Mantovani et al., 2004).  
Thus, this paradigm was investigated in the ESdM-glioma co-culture. ESdM were 
polarized into M1 or M2 subtype before using them for co-culture experiments. M1 
polarization led to a slightly enhanced anti-tumor behavior of ESdM, whereas M2 
treatment only had little effect in comparison to control ESdM. M2 microglia are 
assigned to tumor promoting functions, furthermore M2 microglia strongly resemble 
TAMs (Mantovani et al., 2004b).  
Increased anti-tumor properties in the M1 subtyped are owed to a variety of changes in 
microglia functions. M1 microglia secrete pro-inflammatory and cytotoxic factors such as 
IL-1β, NO and superoxide anions which might play a role in reducing glioma cell 
number (Goerdt and Orfanos, 1999). M1 polarization leads to enhanced production of 
inflammatory CC motif chemokines and IFN-γ responsive chemokines, which recruit NK 
cells and Th1 cells to the tumor site and result in higher tumor resistance (Mantovani et 
al., 2004). It has been shown that inflammation triggers an anti-glioma immune response, 
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higher phagocytic activity and also leads to killing of tumor cells (Auf et al., 2001; 
Nickles et al., 2008). M1 activated microglia are also known to secrete enhanced levels 
of CXCL10, which has an anti-tumor effect and inhibits angiogenesis (Angiolillo et al., 
1995; Farber et al., 1997).  
FACS analysis revealed that M1 polarization also led to an increase in expression of 
phagocytic receptors Trem2 and SiglecH, which will be discussed in detail later on. 
Nevertheless, one has to keep in mind that the subpolarization of microglia is a highly 
sensitive process. Thus, the tumor micromilieu is quite likely to reverse the effects of in 
vitro subpolarization into M1 subtype. This objective could be overcome via usage of 
protein tyrosine phosphatase SHP-1 knock-down cells. SHP-1 is a negative regulator of 
pro-inflammatory gene transcription, thus a lack of SHP-1 results in increased 
inflammation in the CNS (Christophi et al., 2009).  ESdM lacking SHP-1 are likely to be 
immune to the tumor micromilieu and could lead to higher clearance of tumor cells in 
vivo. 
 
4.4.4. Function of DAP12 in microglia-glioma interaction 
DAP12 is a short polypeptide consisting of an extracellular tail, a single transmembrane 
domain and a cytoplasmic ITAM (Turnbull and Colonna, 2007). DAP12 is a signaling 
molecule found in macrophages and microglia that functions via the tyrosine kinase SYK 
and protein kinase ZAP-70 which bind to the ITAM (Turnbull and Colonna, 2007). The 
signaling cascade triggered through protein tyrosine phosphorylation leads via various 
down-stream pathways such as extracellular-signal-regulated kinases (ERKs) to effector 
function and cell activation. Functions include cytokine secrection by macrophages and 
enhanced phagocytosis (Colonna, 2003). It has previously been demonstrated that DAP12 
controls the phagocytic properties of microglia and the inflammatory response followed 
by neuronal death (Takahashi et al., 2005). 
Furthermore, DAP12 intersects with the TLR-pathway and alters the release of TNF-α, 
IL-6 and IL-12, a set of cytokines which is crucial to innate and adaptive immune 
response and pathogen clearance (Hamerman et al., 2009). In regard to tumor response it 
is of interest that mice lacking proper DAP12 function show impaired immune responses 
including non-functional NK cell activation and disabled Th1 response (Tomasello et al., 
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2000; Bakker et al., 2000). Both of these features are well known to be involved in anti-
tumor responses in the CNS. In addition to the pro-inflammatory and phagocytosis-
enhancinc features, DAP12 was also described to mediate inhibitory signals. Primary 
microglia lacking functional DAP12 express higher levels of iNOS, IL-1β and IL-6 
(Roumier et al., 2008). 
In the here presented experiments, the overexpression of DAP12 led to an enhanced anti-
tumor effect of ESdM, which is most likely due to the enhanced phagocytosis. To be 
more precise, the anti-tumor effect appears to be mediated via the ITAM of the DAP12, 
as a dominant negative DAP12 form lacking that motif displays only little anti-tumor 
properties. Without a phosphorylated functional ITAM, kinases are unable to bind and 
downstream signal transduction is blocked.   
In summary, the obtained results underline the discussed role of DAP12 in microglia-
glioma interaction as described in the literature. DAP12 signaling could be a promising 
target for immune therapy in glioma, although one has to keep in mind that DAP12 
signaling affects a broad variety of receptors and functions.  
 
4.4.5. The role of Trem2 and SiglecH 
Phagocytosis has been shown to involve ITAM signaling, which in mammal microglia is 
mainly mediated via DAP12 (Ziegenfuss et al., 2008). Trem2, complement receptor 3, 
signal-regulatory-protein (SIRP) β-1 and SiglecH belong to the DAP12-associated 
receptors (Ivashkiv, 2009; Lanier 2009). To investigate the receptors involved in glioma 
phagocytosis, Trem2 and SiglecH were chosen as representative candidates.  
In both cases, knock-down of the receptors led to a lower phagocytosis rate of glioma 
cells through ESdM and higher proliferation rates of glioma cells in the co-culture. Thus, 
data imply that Trem2 and SiglecH play a role in microglia-glioma interaction and anti-
tumor properties.  
 
SiglecH is a DAP12-associated CD33-related Siglec which is found specifically in mice 
(Crocker et al., 2007). SiglecH signals through the ITAM of DAP12, which is in contrast 
to most siglecs signaling via immunoreceptor tyrosine-based inhibition motif (ITIM). 
Until now, function and ligand of SiglecH remain unclear. However, its involvement in 
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the uptake of antigens and in the modulation of cellular functions via DAP12 signaling 
has been demonstrated (Blasius and Colonna, 2006).  
It could be shown that SiglecH Fc fusion protein binds to glioma cells, but not to 
astrocytes (Beutner and Kopatz, unpublished data). Stimulation of ESdM into M1 
subtype led to an increase in SiglecH expression and phagocytosis rate, thus data implies 
an involvement of SiglecH in phagocytosis activation. This hypothesis is also 
underpinned as knock-down of SiglecH resulted in lower phagocytosis rates. Preliminary 
data gave first clues that sialylation of surface glycoproteins might play a role in SiglecH-
mediated microglia-glioma interaction. Siglecs have also been mentioned in regard to 
cell-targeted therapies. They can be used for the “Trojan horse” strategy in which 
therapeutic agents conjugated to an antibody bind to Siglecs and are efficiently carried 
into the cell (O´Reilly and Paulson, 2009). This property could be used to “load” ESdM 
with therapeutic agents and deliver them into the tumor residuum via tumor-initiated 
microglia attraction. 
One has to bear in mind that SiglecH is exclusively found in mice. Nevertheless, the 
human Siglec16 was shown to be a DAP12-associated receptor and has a similar 
structure like SiglecH (Cao et al., 2008). It would be therefore of interest to investigate 
the role of Siglec16 in human induced pluripotent stem cell derived microglia in 
interaction with human glioma lines such as U87.  
 
Trem2 is a DAP12-associated receptor expressed on myeloid cells such as macrophages 
and microglia. Trem2 was described to be involved in CNS immune homeostasis 
(Neumann and Takahashi, 2007). Alike SiglecH, the ligands of Trem2 are not known so 
far. Its role in phagocytosis has been demonstrated in several studies. Expression of 
Trem2/DAP12 in Chinese hamster ovary cells was shown to enhance immune answer and 
phagocytosis of bacteria (N`Diaye et al., 2009). Takahashi et al. have shown that Trem2-
transduced myeloid precursor cells mediated clearance of tissue debris via phagocytosis 
in EAE (Takahashi et al., 2007).  
In contrast to the before discussed beneficial effects of inflammation in regard to anti-
tumor responsed, Trem2 is a negative regulator of inflammatory responses (Takahashi et 
al., 2007) and its expression on macrophages is decreased after treatment with LPS 
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(Turnbull et al., 2006).  
Stimulation of ESdM towards M1 subtype led to a slight increase in Trem2 expression, 
which might also be responsible for enhanced phagocytosis after stimulation. 
Nevertheless, in comparison to knock-down of DAP12 and SiglecH the effects of the 
Trem2 knock-down were less potent. One might thus assume that Trem2 is not the main 
receptor involved in glioma-microglia interaction. 
 
4.4.6. Evaluation of ESdM as therapeutic tool for glioma 
Although microglia are known to be involved in tumor progression, there is accumulating 
evidence that they might be a suitable tool for therapeutic application.  
Clearly, microglia are situated ideally within the CNS to confront migrating and resident 
tumor cells. Another beneficial property of microglia is their ability to migrate from the 
blood stream to the CNS, which opens up interesting possibilities for therapeutic gene 
transfer into mature CNS tissue and the tumor residuum (Flügel et al., 2001). As 
microglia are closing the gap between the immune-privileged CNS and the peripheral 
immune system, they are an attractive cell type in immunotherapy for glioma (Yang et 
al., 2010). Innate microglia associated with gliomas appear to be incapable of inducing 
effective anti-tumor responses. But if this problem could be overcome by administration 
of ESdM, CNS immunity against tumors could be significantly enhanced. Additionally, 
treatment with ESdM yields less problems than treatment of tumors with neural or 
mesenchymal stem cells (Herrlinger et al., 2000; Aboody et al., 2000; Uhl et al., 2005), 
which all include genetic modifications of the cells. Furthermore, ESdM can be obtained 
in virtually unlimited numbers by differentiation of ESC or iPS obtained from the 
patients, respectively. 
It would be of interest if a beforehand subpolarization of ESdM into the M1 anti-tumor 
subtype would result in an even stronger therapeutic effect. Additionally, chemo-
attractants for cytotoxic immune cells could be added to the ESdM treatment in order to 
maximize the beneficial effect of the therapy. 
To conclude, ESdM might be a suitable and powerful tool for immunobased cell-therapy 
of glioma, though further studies are needed to fully evaluate their therapeutic properties. 
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5. Summary 
Microglia are the resident immune cells of the central nervous system (CNS). They are 
known to have detrimental as well as beneficial effects. To overcome the limitations of 
primary microglia, embryonic stem cell derived microglia precursor cells (ESdM) were 
differentiated out of mouse embryonic stem cells. ESdM showed expression of microglial 
markers such as Iba1, CD45 or CD68, but lacked stem cell markers. Stimulation of 
ESdM with Interferon-γ (IFN- γ) or lipopolysaccharides leads to an up-regulation of 
inflammatory cytokines and to increased phagocytosis. Furthermore, ESdM migrate in a 
dose-dependent manner towards fractalkine CX3CL1. Gene expression of ESdM 
resembles that of primary microglia and preliminary data indicate that they can be 
subpolarized into a neuro-toxic or a neuro-protective subtype by IFN-γ or interleukin-4.  
After lentiviral transduction of ESdM with Neurotrophin 3 (NT3), they were applied to 
experimental autoimmune encephalomyelitis (EAE) afflicted mice to reveal possible 
therapeutic chances for the treatment of multiple sclerosis (MS). EAE mice treated with 
NT3-green fluorescent protein (GFP)-ESdM showed stable recovery of clinical 
symptoms, accompanied by less demyelination and less axonal damage in the spinal cord 
tissue. ESdM migrated to the lesions and promoted an anti-inflammatory cytokine 
profile. Furthermore, in close proximity to the NT3-GFP-ESdM, the axonal growth 
protein GAP-43 could be found, indicating neural regeneration due to the presence of 
NT3. To summarize, NT3-GFP-ESdM can be considered a promising tool for therapeutic 
approaches to EAE as a model of MS. 
ESdM were also applied in co-culture systems with glioma cells to determine their 
potential for therapeutical approaches. ESdM phagocytosed glioma cells and reduced 
glioma cell number in vitro. Phagocytosis and proliferation inhibition were enhanced 
through subpolarization of ESdM into M1 subtype. The anti-tumor effects were most 
likely mediated via DAP12 and the DAP12-associated receptors SiglecH and Trem2. 
Knockdown of these molecules decreased the anti-tumor activity of ESdM, while 
overexpression of DAP12 resulted in stronger anti-tumor effects. Thus, ESdM could 
provide functions to also fight glioma in vivo. 
In summary, ESdM might provide a broad range of possible applications in therapeutical 
approaches of CNS diseases. 
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